The role of adiponectin and the adipocyte in energy metabolism and inflammation by Jacobi, Sheila Kay
Purdue University
Purdue e-Pubs
Open Access Dissertations Theses and Dissertations
Fall 2014
The role of adiponectin and the adipocyte in
energy metabolism and inflammation
Sheila Kay Jacobi
Purdue University
Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations
Part of the Agriculture Commons, Animal Sciences Commons, Animal Studies Commons, and
the Nutrition Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation





















To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, 
Publication Delay, and Certification/Disclaimer (Graduate School Form 32), this thesis/dissertation  
adheres to the  provisions of Purdue University’s “Policy on Integrity in Research” and the use of 
copyrighted material. 
Sheila Kay Jacobi












THE ROLE OF ADIPONECTIN AND THE ADIPOCYTE IN ENERGY 
METABOLISM AND INFLAMMATION 
A Dissertation 




Sheila Kay Jacobi  
In Partial Fulfillment of the 
Requirements for the Degree 
of 
Doctor of Philosophy 
December 2014  
Purdue University 









With love and appreciation to my parents and family; 
 
Mom and Dad 
Julie and Gary, Kaylyn, Garrett, and Nathan 
Debbie 
 









There are so many people which I need to say thank you to for helping me along 
this journey.  First, I need to say thank you to my advisor and mentor, Dr. Michael 
Spurlock.  What can I say besides what a ride it has been, and I know I would not be 
standing here today without your faith in me.  Every challenge you have presented has 
changed my thinking along this road to becoming a better scientist.  I know that I have 
grown more as a person  here than ever before in my life, and for that I will always be 
grateful.  I greatly appreciate the contributions of my committee, Drs. Paul Collodi, 
Diane Moody, and Fred Regnier.  Their input into my program has been of great value.  I 
would like to say a special thank you to Dr. Todd Applegate for his help and support. 
To my lab mates from the Spurlock lab who have inspired me and spurred me on 
in times of doubt their support is much appreciated: Joanne, Brittany, Kola, Nick, Jeremy,  
and Stephanie.  To the people at the farms and the guys in the meat lab who always made 
me laugh about the project that went on forever.  I could not stand here today without the 
help of Mike, Gary and Bob who were faithful every Tuesday and Thursday morning in 
getting me tissue.  To the many others behind the scenes who make this department run 
efficiently, you know who you are!  To all the graduate students I have met and learned 
from on this journey. 
The memories that make life truly special are created by the people we meet along 
this journey.  I feel blessed to get to leave here with friendships I will cherish forever.  
First, Brittany Barrett was a terrific undergraduate researcher, but mostly a great friend 
whose faith in me never wavers.  I would not have made it through this last year without 
Marie Stahl, whose monthly girls’ nights helped me keep some resemblance of balance in 





journey would not have been complete without Lindsay Wilson and Kristi Thompson. 
Lindsay, I guess they say the hard times make us stronger and can bring us closer 
together to the important people in your life.  Thank you for always being a voice of 
reason!  Kristi, your tenacious drive and dedication to all of life is truly something that 
everyone should aspire to have. Your friendship has been pleasant surprise to me and a 
saving grace over the last this year.  Lastly, my roommate and partner in crime, Tara 
McDaneld, what can I say I guess we really are “big kids now!”  Your support and 
friendship to me defines the meaning of true friendship!   
Finally, this would not have been possible without my biggest supporters, my 
parents, siblings and their families: Dad, Mom, Julie, Gary, Kaylyn, Garrett, Nathan, and 
Debbie.  Their love, encouragement and support are the foundation for the person I am 
today.  I will never be able to say Thank You enough for all you have done for me.  I 
cherish you all and no matter where this road leads me, and I carry each of you with me 
in my heart!  And last, but definitely not least, my big white fur ball, Jasper, who is 
always happy to see me no matter what is going on in life!  And finally to God above for 







TABLE OF CONTENTS 
Page 
LIST OF TABLES ........................................................................................................... viii 
LIST OF FIGURES ........................................................................................................... ix 
LIST OF ABBREVIATIONS ........................................................................................... xii 
ABSTRACT ...................................................................................................................... xv 
CHAPTER 1. INTRODUCTION .................................................................................. 1 
1.1 Introduction .......................................................................................................... 1 
1.2 Adipocytes and energy balance ............................................................................ 2 
1.3 Adipocytes and AMPK ......................................................................................... 4 
1.4 Adipocytes, inflammation and interleukin-6 ........................................................ 6 
1.5 Adipocytes, inflammation and tumor necrosis factor α ....................................... 9 
1.6 Adiponectin: adipocyte derived protein combating insulin resistance ............... 10 
1.7 Metabolic functions of adiponectin .................................................................... 13 
1.8 Adiponectin receptors ......................................................................................... 15 
1.9 PPARs and inflammation ................................................................................... 16 
1.10   Insulin resistance ................................................................................................ 19 
1.11   The insulin receptor and signaling pathways ..................................................... 20 
1.12   Putting it together:  adipocytes, nutrient excess, inflammation and adiponectin 23 
1.13   References .......................................................................................................... 26 
CHAPTER 2. CLONING AND EXPRESSION OF PORCINE ADIPONECTIN, AND 
ITS RELATIONSHIP TO ADIPOSITY, LIPOGENESIS, AND THE ACUTE PHASE 
RESPONSE ............................................................................................................... 37 





                                                                                                                                       Page 
2.2 Introduction ........................................................................................................ 38 
2.3 Materials and Methods ....................................................................................... 40 
2.4 Results ................................................................................................................ 48 
2.5 Discussion ........................................................................................................... 51 
2.6 References .......................................................................................................... 57 
CHAPTER 3. ADIPONECTIN REGULATES THE EXPRESSION OF GENES 
ASSOCIATED WITH FATTY ACID SYNTHESIS AND OXIDATION IN PRIMARY 
PIG ADIPOCYTES .......................................................................................................... 77 
3.1 Abstract ............................................................................................................... 77 
3.2 Introduction ........................................................................................................ 78 
3.3 Methods .............................................................................................................. 80 
3.4 Results ................................................................................................................ 84 
3.5 Discussion ........................................................................................................... 88 
3.6 References .......................................................................................................... 93 
CHAPTER 4. PRO-INFLAMMATORY CYTOKINES AND GLUCOSE 
REGULATE EXPRESSION OF ADIPONECTIN RECEPTORS IN PORCINE 
ADIPOCYTES  ........................................................................................................... 106 
4.1 Abstract ............................................................................................................. 106 
4.2 Introduction ...................................................................................................... 107 
4.3 Methods ............................................................................................................ 109 
4.4 Results .............................................................................................................. 112 
4.5 Discussion ......................................................................................................... 115 
4.6 References ........................................................................................................ 118 
CHAPTER 5. HYPERGLYCEMIA-INDUCED IMPAIRMENT OF ADIPOCYTE 
FUNCTION ............................................................................................................. 128 
5.1 Abstract ............................................................................................................. 128 
5.2 Introduction ...................................................................................................... 129 
5.3 Methods ............................................................................................................ 131 





                                                                                                                                   Page 
5.5 Discussion ......................................................................................................... 136 
5.6 References ........................................................................................................ 139 
CHAPTER 6. SUMMARY ........................................................................................ 151 
6.1 References ........................................................................................................ 155 







LIST OF TABLES 
Table .............................................................................................................................. Page 






LIST OF FIGURES 
Figure ............................................................................................................................. Page 
Figure 1.1 Hypothesis for the autocrine role of adiponectin in maintaining energy balance 
in the adipocyte and inhibiting inflammation in adipose tissue ........................................ 25 
Figure 2.1.  Nucleotide sequence and translation of porcine adiponectin. ....................... 70 
Figure 2.2.  Northern blot analysis of adiponectin mRNA in pig adipose tissue ............. 71 
Figure 2.3 Western blot analysis of pig serum using a monoclonal anti-human 
adiponectin antibody described previously (ANOC 9108; 19, 20)................................... 72 
Figure 2.4.  Regulation of lipogenesis in isolated pig adipocytes by recombinant pig 
adiponectin. ....................................................................................................................... 73 
Figure 2.5 Expression of adiponectin mRNA in isolated pig adipocytes treated with 
selected pro-inflammatory cytokines and isoproterenol ................................................... 74 
Figure 2.6.  Relative serum concentrations of adiponectin in pigs challenged with an i.v. 
infusion of E. coli .............................................................................................................. 75 
Figure 2.7 Relative serum adiponectin concentrations (A) subcutaneous backfat thickness 
(B) in a lean vs. a fatter genotype of pigs. ........................................................................ 76 
Figure 3.1 Regulation of adiponectin mRNA abundance in porcine adipocytes. ............. 96 
Figure 3.2Effect of adiponectin on AMPK mRNAabundance pig adipocytes from 0 to 6 
hours. ................................................................................................................................. 97 






Figure                                                                                                                             Page 
Figure 3.4.Effect of adiponectin on AMPK activity in pig adipocytes ............................ 99 
Figure 3.5Effect of adiponectin on ACC mRNA abundance in pig adipocytes. ............ 100 
Figure 3.6  Effect of adiponectin and IL-6 on phosphorylation of ACC in pig adipocytes.
......................................................................................................................................... 101 
Figure 3.7.Effect of adiponectin on PPARα mRNA abundance in pig adipocytes. ....... 102 
Figure 3.8Effect of adiponectin on abundance of PPARα protein pig adipocytes. ........ 103 
Figure 3.9. Effect of adiponectin on ACO mRNA abundance in pig adipocytes. .......... 104 
Figure 3.10 Effect of adiponectin on UCP3 mRNA abundance in pig adipocytes......... 105 
Figure 4.1 Regulation of AdipoR1 mRNA overtime in pig adipocytes. ........................ 120 
Figure 4.2Regulation of AdipoR2 mRNA overtime in pig adipocytes. ......................... 121 
Figure 4.3Effect of TNFa and IL-6 on AdipoR1 mRNA abundance in pig adipocytes 
under euglycemic and hyperglycemic conditions. .......................................................... 122 
Figure 4.4 Effect of TNFa and IL-6 on AdipoR2 mRNA abundance in pig adipocytes 
under euglycemic and hyperglycemic conditions. .......................................................... 123 
Figure 4.5 Regulation of AdipoR1 protein by pro-inflammatory cytokines under 
euglycemic and hyperglycemic conditions. .................................................................... 124 
Figure 4.6 Regulation of AdipoR2 protein by pro-inflammatory cytokines under 
euglycemic and hyperglycemic conditions ..................................................................... 125 
Figure 4.7 Regulation of AdipoR1 protein by adiponectin and darglitazone under 
euglycemic and hyperglycemic conditions. .................................................................... 126 
Figure 4.8 Regulation of AdipoR2 protein by adiponectin and darglitazone under 





Figure                                                                                                                             Page 
Figure 5.1 Hyperglycemic inhibition of insulin stimulated glucose uptake in pig 
adipocytes ....................................................................................................................... 142 
Figure 5.2 Hyperglycemic inhibition of insulin stimulated glucose uptake in 3T3-L1 
adipocytes ....................................................................................................................... 143 
Figure 5.3 Hyperglycemic regulation of Phospho-Akt in pig adipocytes. ..................... 144 
Figure 5.4 Hyperglycemic regulation of Total Akt protein in pig adipocytes. ............... 145 
Figure 5.5 Hyperglycemic regulation of phosphorylation of the insulin receptor in pig 
adipocytes. ...................................................................................................................... 146 
Figure 5.6 Hyperglycemic regulation of phosphorylation of Akt in 3T3-L1 adipocytes 147 
Figure 5.7 Hyperglycemic regulation of total Akt protein in 3T3-L1 adipocytes .......... 148 
Figure 5.8.Hyperglycemic regulation of phosphorylation of the insulin receptor in 3T3-
L1 adipocytes .................................................................................................................. 149 
Figure 5.9Adiponectin regulation of intracellular ROS activity in 3T3-L1 adipocytes 






LIST OF ABBREVIATIONS 
ACC   acetyl CoA carboxylase 
adipoR1   Adiponectin receptor 1 
adipoR2  Adiponectin receptor 2 
ADP   Adenosine di-phosphate 
AICAR  5-Aminoimidazole-4-carboxamide ribonucleoside 
AMP   Adenosine mono-phosphate 
AMPK   AMP-activated protein kinase 
AP-1   activator protein-1 
ATP   Adenosine tri-posphate 
C/EBP   CAAT/enhancer-binding protein 
COX 2   Cyclooxygenase 2 
CPT-1   carnitine palmitoyltransferase 
FA   fatty  acids 
FFA   Free fatty acids 
Foxo1   Forkhead transcription factor 
g   Gram 
gAdn   Globular adiponectin 





GSK   glycogen synthase kinase  
h   Hour 
HIV   human immunodeficiency virus 
ICAM-1  endothelin-1 intracellular adhesion molecule-1  
IGF   insulin-like growth factor 
IL-12   Interleukin 12 
IL-1β   Interleukin 1β 
IL-6   interleukin-6  
iNOS   inducible nitric oxide synthase 
IRR   insulin receptor-related receptor 
IRS   Insulin receptor substrate 
IRS-1   insulin receptor substrate-1 
IκB   nuclear factor kappa B inhibitory factor 
kg   Kilogram 
L   Liter 
LPS   lipopolysaccaride 
mg   Milligram 
min   Minute 
mL   Milliliter 
MMP-9  matrix metalloproteinase 
mRNA   Messenger ribonucleic acid 
mTOR   mammalian target of rapamycin 






pAdn   porcine adiponectin 
PGF1α   6-keto platelet growth factor 1α 
PI3-kinase  phosphoinositide-3 kinase 
pmol   Picomoles 
PPAR   peroxisome proliferators-activated receptor 
rel   Relish 
SH2   Src-homology-2 
TG   triglyceride 
Thr-172  threonine-172  
TNFR1  tumor necrosis factor α receptor 1 
TNFR2  tumor necrosis factor α receptor 2 
TNFα   tumor necrosis factor α  
TZD   thiazolidinediones 
VCAM-1  vascular cell adhesion molecule-1 
WAT   white adipose tissue 
μg   Micro-gram 








Jacobi, Sheila Kay. Ph.D., Purdue University, December 2014. The Role of Adiponectin 
and the Adipocyte in Energy Metabolism and Inflammation. Major Professor: Michael 
Spurlock and Todd Applegate. 
 
 
Adipocytes play an important role in the regulation of whole body energy balance.  
They synthesize and secrete many hormones which communicate with the diverse 
physiological systems of the body.  However, when adipose tissue physiology is in a state 
of imbalance the communication between adipocytes and the rest of the body is 
compromised and can lead to metabolic disease.  The adipocyte derived hormone 
adiponectin is efficacious in reversing insulin resistance in rodent models of 
lipodystrophy and obesity.  Therefore, a series of experiments were conducted to 
characterize the autocrine role of adiponectin in modulating fatty acid metabolism and 
inflammation in the pig.  In the first study, we cloned and sequenced the porcine 
adiponectin open reading frame and evaluated the regulation of adiponectin, in vitro and 
in vivo.  The porcine sequence shares approximately 88, 86, 85 and 83% homology with 
the dog, human, cow and mouse adiponectin, respectively, and 79-83% similarity with 
dog, human, cow and mouse proteins at the amino acid level, based on the translated 
porcine sequence and GenBank submissions for the other species.  Analysis of serum 






adiponectin concentrations are higher (P < 0.01) in lean pigs than in the fatter line, and 
that the difference is established relatively early in the growth curve.  Incubating pig 
adipocytes for 6 hours with recombinant pig adiponectin also resulted in an approximate 
30% reduction (P < 0.05) in lipogenesis compared with adipocytes under basal conditions 
and with those incubated in the presence of insulin. 
Based on in vivo and in vitro data showing adiponectin is positively correlated 
with leanness and reduces lipogenesis in porcine adipocytes, experiment investigated 
adipocyte lipid metabolism.  In a series of cell culture studies for experiment two, we 
further investigated the role of adiponectin in modulating lipid metabolism by measuring 
mRNA abundance of genes associated with fatty acid synthesis and oxidation in porcine 
adipocytes. Adiponectin transiently increased (2-6.5 fold, P < 0.05) the expression of 
acetyl Co-A carboxylase (ACC), AMP activated kinase (AMPK), acyl Co-A oxidase 
(ACO) and peroxisome proliferator activated receptor-α (PPARα).  After the initial 
increase in mRNA abundance, there was either a return to initial levels of expression 
(PPARα), a significant reduction (AMPK), or a cyclic pattern of expression (ACC, ACO).  
The abundance of the uncoupling protein-3 (UCP3) transcript was not influenced by 
adiponectin until the final measure at 360 minutes, at which time it was increased 3.8-
fold (P < 0.05).  Collectively, these data indicate that adiponectin acts through 
autocrine/paracrine signaling pathways to coordinately regulate lipid metabolism in the 
adipocyte, and may thus be a determinant of adipocyte size and overall lipid 
accumulation. 
Experiment three was designed to examine anti-inflammatory properties of 






adiponectin receptors, adipoR1 and adipoR2.  Cells were incubated ± TNFα or IL-6 (30 
ng/mL), with or without pretreatment of 10 μM AG490, in hyper-glycemic or normo-
glycemic conditions for 6 h.  There was no effect of cytokines at 5.5 mM glucose for R1 
expression.  However, there was a trend for a down-regulation of R2 by AG490-TNFα (P 
< 0.07).  At 25 mM glucose, there was an increase in R1 by AG490-TNFα treatment (P = 
0.06).  R2 was marginally reduced by IL-6, but there was a reduction (P < .01) with 
AG490 plus IL-6.  High glucose caused a reduction of both receptors, whereas TNFα 
increased both in the high glucose media.   R1 (P < 0.1) and R2 (P < 0.05) were further 
elevated by AG490 plus TNFα in high glucose.  Interestingly, IL-6 and AG490 plus IL-6 
(P < 0.05) reduced R1 and R2 expression, but only in the high glucose media.  
Collectively, these data indicate that the effects of TNFα and IL-6 on adiponectin 
receptor expression are influenced by glucose concentration, and that the JAK-STAT 
pathway may be a determinant of adiponectin receptor expression.   
In the final experiment, the effects of hyperglycemia on insulin sensitivity in pig 
adipocytes, and 3T3-L1 adipocytes were examined.  In pig adipocytes, concentrations of 
25 and 40 mM glucose inhibited insulin stimulated glucose uptake (P < 0.05), that could 
not be reversed by addition of adiponectin to the culture media.  To examine if 
hyperglycemic conditions were associated with impaired insulin signaling pig adipocytes 
were cultured in euglycemic and hyperglycemic conditions and insulin receptor and Akt 
phosphorylation were measured by semiquantitative Western blots.  However, insulin 
resistance in primary pig adipocytes could not be attributed to changes in protein 
phosphosphorlation of the insulin receptor or its down-stream target Akt (P > 0.05).  To 






3T3-L1 mouse derived adipocytes were used.  Similar to the effects seen in acute porcine 
adipocyte cultures hyperglycemia inhibited insulin stimulated 2-deoxyglucose uptake in 
3T3-L1 adipocytes (P < 0.05), and 24 hour treatment with adiponectin could not reverse 
the insulin resistance.  Again, difference in phosphorylation of the insulin receptor and 
Akt could not be detected in hyperglycemic culture cells compared with control cells.  
Interestingly, although adiponectin did not appear to impact insulin signaling pathways in 
under hyperglycemic conditions it did have an effect on inflammatory pathways in the 
adipocyte.  Adiponectin reduced the production of intracellular ROS in 3T3-L1 
adipocytes cultured in hyperglycemic conditions (P < 0.05).  Taken together these data 
implicate adiponectin suppressing intracellular inflammation during hyperglycemia, but 






CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Animal growth, development and maintenance require complex integration of 
signals from peripheral tissues.  Thus, communication among physiologic systems and 
tissues is critical to homeostasis. Recent advances in adipocyte physiology have changed 
the face of white adipose tissue (WAT) by defining the adipocyte as an active endocrine 
cell, rather than a simple passive reservoir of surplus energy.   The adipocyte is now 
recognized to have pleiotropic functions involved in energy metabolism, inflammation 
and metabolic disease states. The adipocyte synthesizes and secretes many molecules that 
regulate processes involved in fat storage, feed intake, reproduction, immune function, 
and energy balance and metabolism. 
Understanding the role of the adipocyte in integrated systems physiology is of 
paramount importance due to its recent implications in inflammatory states and immune 
modulation (Fantuzzi, 2005; Xu et al., 2003b).  First, the development of obesity is 
associated with chronic states of positive energy balance which has also been linked to 
chronic inflammation (Chandra, 1996).  Interestingly, ablation of adipose tissue in animal 
models of lipodystrophy is also associated with chronic immune stimulation (Gavrilova 





immune system, and both starvation (Chandra, 1996; Nova et al., 2002) and excessive 
adipose accumulation lead to impaired immune function and increased disease 
susceptibility (Klasing, 1998; Marti et al., 2001). These and other data clearly indicate a 
link between WAT, regulation of energy balance, and the immune system. 
 
1.2 Adipocytes and energy balance 
Understanding the integral role of the adipocyte in regulating energy storage and 
expenditure is a key component of gaining a comprehensive view of energy balance.  
Historically, humans consumed food for survival and maintained energy balance because 
their energy input was similar to their energy expenditure.  However, as times have 
advanced food has become plentiful and lifestyles have become more sedentary. These 
changes favor a positive energy balance, and therefore an increased prevalence of 
obesity.   
 Traditionally adipose tissue has been viewed as only a passive energy storage 
depot.  However, there is substantial evidence indicating that body fat content is 
controlled, at least partially, by the metabolism of adipose tissue itself.  First, human 
genome scans for obesity-related candidate genes identified several genes which play  
critical roles in adipocyte biology (Arner, 2000).  Second, through the use of transgenic 
mouse models, it is clear that modifications to adipose tissue result in a high incidence of 
obesity prone or resistant animals, depending upon the genetic modification (Kopecky et 
al., 2001).  For example, adipose-specific glucose transporter protein 4 (GLUT4) 
knockout mice develop insulin resistance in skeletal muscle and liver (Abel et al., 2001), 





relationship between plasma leptin and body weight, and are protected against age-related 
and hypothalamic lesion-induced obesity (Bluher et al., 2002).  The metabolic changes 
induced in adipose tissue in these transgenic models were pivotal to the altered accretion 
of body fat and the development of metabolic disorders.  It has been clearly demonstrated 
that insulin resistance is a commonality of obesity and the pathogenesis of metabolic 
syndrome-associated disorders (Rossmeisl et al., 2003; Xu et al., 2003).  In models of 
obesity, it is thought the heightened deposition of lipid in peripheral tissues results in 
insulin resistance and this increased lipid accumulation in muscle and liver is due to an 
increased release of fatty acids (FA) from hypertrophic fat cells (Perseghin et al., 2003).  
Moreover, the hypertrophied adipocyte becomes resistant to insulin, resulting in lower 
plasma triglyceride (TG) clearance and increased FA release from WAT.  In contrast, 
others have reported that insulin resistance is a function of a deficiency of WAT 
(Gavrilova et al., 2000; Moitra et al., 1998).  In these conditions, circulating FA are 
elevated due to the lack of capacity of the adipocyte to buffer circulating FA 
concentrations.  As a result, other organs become reservoirs for lipid and develop insulin 
resistance (Kim et al., 2000).  In addition to fatty acids, other nutrients have also been  
implicated in the development of cellular insulin resistance (Patti, 1999).  The infusion of 
amino acids or prolonged hyperglycemia are both implicated in sustained insulin 
resistance. 
In addition to nutrient regulation of energy balance, adipocyotokines have a 
pronounced endocrine impact on peripheral tissues and a paracrine/autocrine regulation 
of adipocyte cellular energy balance.  Some adipocytokines of particular interest are 





have been implicated in insulin sensitivity, cellular energy metabolism and whole body 
energy balance (Fantuzzi, 2005).  Thus, adipocytes and adipose tissue play a distinct and 
critical role in energy balance.  
 
1.3 Adipocytes and AMPK 
 One of the key enzymes involved in cellular energy balance is AMP-activated 
protein kinase (AMPK). This kinase is a conserved sensor of cellular energy status, and is 
implicated as a central component in regulation of cellular energy metabolism (Kahn et 
al., 2005).  It is a downstream component of a kinase cascade which is activated by a 
drop in energy status of the cell.  If ATP is consumed faster than its rate of synthesis, 
ATP levels fall and AMP accumulates.  The increase in the AMP:ATP ratio triggers the 
activation of AMPK, and leads to the activation of a large number of downstream targets.  
The overall effects of AMPK activation are to switch off energy-consuming pathways 
and switch on energy-producing processes, to restore the energy balance within the cell 
(Hardie et al, 2003). Because the reaction catalyzed by adenylate cyclase (2ADP ↔ ATP 
+ AMP) is always held near equilibrium, the cellular AMP:ATP ratio varies roughly as 
the square of the ADP:ATP ratio, making the AMP:ATP ratio a more sensitive index of 
energy status (Kahn et al., 2005).   
AMPK exists as a heterotrimeric enzyme comprised of a catalytic α-subunit and 
regulatory β and γ subunits. The complexity of regulation and control which this enzyme 
exerts on cellular metabolism is evident by the fact each subunit is encoded by multiple 





is also allosteric regulation of the enzyme complex by AMP which promotes activation 
by phosphorylation of the kinase domain at threonine-172 (Thr-172) in the activation 
loop (Kahn et al., 2005).  Dephosphorylation of AMPK at Thr-172 is also inhibited by 
AMP.  The regulation of phosphorylation and dephosphorylation by AMP seems to be 
due to binding of ligand to substrate, AMPK, and not a change in activity of upstream 
kinases and phosphatases.  The extreme sensitivity of AMPK to AMP:ATP ratios is 
demonstrated by how AMP activates the enzyme complex by three mechanisms 
(allosteric activation, phosphorylation, and inhibition of dephosphorylation) and all three 
mechanism are antagonized by high cellular ATP (Hardie, 2003).   
Until the last several years, understanding the regulation of AMPK was focused 
on acute cellular energy balance.  However, AMPK responds to the adipocyte-derived 
hormones leptin (Minokoshi et al., 2002) and adiponectin (Yamauchi et al., 2002), and 
evidence is mounting that AMPK is linked directly to whole body energy metabolism. 
Leptin activates AMPK in skeletal muscle to increase fatty acid oxidation (Minokoshi et 
al., 2002).  Adiponectin activates AMPK in skeletal muscle, isolated adipocytes, and liver 
to increase fatty acid metabolism, glucose utilization and inhibit glucose production, 
respectively (Berg et al., 2001; Wu et al., 2003; Yamauchi et al., 2002).    
The interactions among lipid metabolism, energy balance and inflammation in 
abnormal metabolic states are unique relationships which could tie the role of nutrient 
excess seen in obesity and related metabolic conditions to the low level inflammatory 
state.  Recently Lihn et al. (2004) reported that 5-aminoimidazole-4-carboxamide 





activate AMPK and dose-dependently increase adiponectin gene expression in human 
adipose tissue.  They also demonstrated AICAR attenuates the release of TNFα and IL-6 
from human adipose tissue, and the reduced concentrations of the cytokines lead to 
increased levels of adiponectin.  Taken together these results indicate AMPK activity 
might play a role in the insulin-sensitizing effects of AICAR and adiponectin.  This is 
consistent with findings that adiponectin attenuates the translocation of nuclear factor 
kappa B (NFκB) to the nucleus of adipocytes stimulated with lipopolysacharide (LPS) 
(Ajuwon et al., 2004).  Attenuation of NFκB translocation is coupled with an expected 
decrease in production of pro-inflammatory cytokines.   
 
1.4 Adipocytes, inflammation and interleukin-6 
 Interleukin-6 is produced in many cell types and seems to have pro-inflammatory 
and anti-inflammatory effects, depending on the cell type, assay system and timing of 
exposure (Ohshima et al., 1998; Tilg et al., 1994).  In the recent years, studies show that 
adipose tissue is a major site of  IL-6 secretion  and accounts for as much as 15-35% of 
circulating levels (Fried et al., 1998; Mohamed-Ali et al., 1997).  Maachi et al. (2004) 
demonstrated circulating IL-6 concentrations are highly correlated with adipose mass.  
However, concentrations within different adipose tissue depots vary depending on the 
depot.  Fried et al. (1998) reported 3 times as much IL-6 release from the omental adipose 
than the subcutaneous depot, and also suggested the origin of the IL-6 was only 10% 





 Increasing circulating IL-6 levels are highly correlated with insulin resistant states 
such as obesity, impaired glucose tolerance and type II diabetes (Fernandez-Real et al., 
2001; Kado et al., 1999; Mohamed-Ali et al., 1997; Muller et al., 2002; Pickup et al., 
1997; Straub et al., 1996).  The physiological importance of IL-6 may be closely related 
to its high correlation with body mass index (BMI), percent fat mass, systolic and 
diastolic blood pressure, and fasting insulin levels (Fernandez-Real et al., 2001; 
Mohamed-Ali et al., 1997).  Additionally, IL-6 is associated with increased risk for 
development of type II diabetes, independent of percent of body fat (Pradhan et al., 2001).   
 Regulation of IL-6 secretion from the adipocyte is quite complex.  Stimulation of 
the adipocyte with β-agonists (Fasshauer et al., 2003; Vicennati et al., 2002), IL-6 
(Fasshauer et al., 2003; Lagathu et al., 2003), interleukin-1β (Flower et al., 2003), TNFα 
(Fasshauer et al., 2003) and endotoxin (Lin et al., 2000) result in IL-6 secretion.  Weigert 
et al. (2004) also reported that free fatty acids modulate IL-6 secretion from the adipocyte.  
This is intriguing, and raises the question as to whether adipocytokine secretion profiles 
can be modulated by dietary components and metabolic substrates.  In states of metabolic 
imbalance, such as obesity and lipodystrophy, the metabolic profiles are associated with 
elevated plasma fatty acids and glucose.  Although adipocytokine secretion from the 
adipocyte is complex, it is intriguing that IL-6 secretion is regulated in vitro by other pro-
inflammatory cytokines.  Thus, a greater amplification of inflammation during states of 
metabolic imbalance likely exacerbates insulin resistance. 
 The study of IL-6 gene expression in other cell types is quite extensive and is 
regulated by several transcription factors.  The most prominent of these response 





factor is composed of homodimeric and heterodimeric proteins from the relish (rel) 
family (Ghosh et al., 1998); review).  Cellular NFκB is found in one of two states:  the 
inactive state where it is bound to its cellular inhibitor, IκB, or the active state where 
phosphorylated IkB disassociates from NFkB and it translocates to the nucleus where it 
binds its response element.  The regulation of this process is dependent upon 
phosphorylation of IκB, its ubiquination and ultimate degradation, which frees NFκB for 
translocation.  This IL-6 transcription factor is probably the best studied because its 
activation seems to be essential for final activation of the IL-6 gene promoter (Vanden 
Berghe et al., 2000).   
There are other transcription factors involved in IL-6 gene expression, and 
Matsusaka et al. (1993) suggested multiple transcription factors are required for maximal 
stimulation of IL-6 gene expression.  By contransfection of NF-IL-6 (C/EBP) and NFκB 
p65, these researchers found synergistic activation of the IL-6 promoter reporter construct.  
The complexity of the molecular regulation of IL-6  transcription is apparent in that 
others have found that activation of NFκB alone does not always lead to IL-6 expression 
(Legrand-Poels et al., 2000).  Nonetheless, the adipocyte expresses significant levels of 
NFκB (Ajuwon et al., 2004; Ruan et al., 2002), C/EBPβ and C/EBPδ (Tang et al., 2004), 
and activator protein-1 (AP-1).  Therefore, this cell certainly has the molecular machinery 
needed to produce significant levels of IL-6, and it is not surprising that the adipocyte 








1.5 Adipocytes, inflammation and tumor necrosis factor α  
 TNFα is synthesized as a 26-kD transmembrane pro-cytokine, which is cleaved to 
yield a 17 kD soluble molecule.  Both of these proteins are capable of creating a 
metabolic and inflammatory response (Sethi and Hotamisligil, 1999).  TNFα has two 
receptors type 1 (TNFR1) and type 2 (TNFR2), which are expressed ubiquitously, and 
dimerize upon ligand binding.  Receptor subtype seems to have unique signaling 
properties in the adipocyte (Fruhbeck et al., 2001).  Understanding the signaling 
properties of TNFα in adipocytes and other cells could help discern the pathogenesis of 
metabolic diseases associated with insulin resistance since tissue expression and 
circulating TNFα are elevated during this physiological state (Maachi et al., 2004).      
Understanding the autocrine and paracrine effects of  adipocyte-derived TNFα  
may present a clearer picture of whole body energy balance, given that this cytokine 
plays an important role in lipid metabolism (Sethi and Hotamisligil, 1999).  First, 
treatment of tumor-bearing (cachexic) rodents with anti- TNFα antibodies protects 
against lipid metabolism abnormalities (Carbo et al., 1994).  Second, in obesity models 
elevated TNFα seems to stimulate lipolysis (Ramsey, 1996), thus increasing free fatty 
acids (FFA) in circulation, which is a hallmark of metabolic diseases associated with 
insulin resistance. Moreover, TNFα-/- mice are characterized by lower levels of 
circulating concentrations of FFA and TG (Uysal et al., 1997; Ventre et al., 1997).  
Finally, treatment of cultured adipocytes with TNFα stimulates lipolysis, as indicated by 
the release of FFA in to the culture media (Green et al., 1994; Kawakami et al., 1987).  
This is substantial evidence that TNFα promotes the hyperlipidemia that is common in 






The mechanisms by which TNFα is involved in the development of insulin 
resistance are still being unraveled, and are likely to involve complex intracellular 
communications.  There are indications that TNFα directly impairs insulin signaling in 
the adipocyte by down-regulating insulin-stimulated glucose uptake (Hotamisligil et al., 
1994).  Stephens and Pekala (1992) reported TNFα reduces insulin receptor tyrosine 
kinase activity at low concentrations, and at higher levels, will decrease insulin receptor, 
insulin receptor substrate-1 (IRS-1) and GLUT4  expression.  Furthermore, TNFα 
increases serine
307
 phosphorylation of IRS-1, which causes conformational changes in the 
protein which inhibit binding to the insulin receptor to attenuate downstream signaling 
(Rui et al., 2001).  Collectively, these data indicate that TNFα plays a direct role in 
impairing nutrient clearance by adipocytes and other peripheral tissues to perpetuate the 
hyperglycemia and hyperlipidemia associated with insulin resistance.   
 
1.6 Adiponectin: adipocyte derived protein combating insulin resistance 
Adiponectin is a relatively new adipocytokine that was cloned independently by 
four separate groups in the mid-1990s (Scherer et al, 1995; Maeda et al, 1996; Hu et al, 
1996; Nakano et al, 1996).  Since that time, it has become clear adiponectin plays an 
important role in regulation of insulin sensitivity, glucose homeostasis, and lipid 
metabolism.  Adiponectin mRNA in fat and plasma hormone concentrations are 
suppressed with the development of insulin resistance and obesity (Hu et al, 1996; Hotta 
et al, 2000; Weyer et al, 2001).  In agreement with these data, adiponectin expression 
increases with weight loss and improved insulin sensitivity (Yang et al, 2001; Milan et al, 






increases synthesis and secretion of adiponectin (Yamauchi et al, 2001; Maeda et al, 
2001; Yu et al, 2002; Yang et al, 2002; Motoshima et al, 2002). However, the 
mechanisms by which adiponectin is regulated remain somewhat unclear. Since insulin 
sensitivity is highly correlated with adiponectin concentrations it might be expected that 
insulin regulates adiponectin.  Fasting plasma insulin concentrations are negatively 
correlated with plasma adiponectin, and chronic treatment of 3T3-L1 adipocytes with 
insulin also have reduced adiponectin mRNA expression (Yu et al, 2002; Fasshauer et al, 
2002; Bluher et al, 2002).  In contrast, others have found that treatment of human visceral 
adipocytes and mouse brown adipocytes with insulin increases adiponectin mRNA 
expression (Halleux et al, 2001; Viengchareun et al, 2002).  These data suggest there is 
differential regulation of adiponectin across species and adipose tissue depots.   
Hormones involved in insulin resistance seem to play an antagonistic role on 
adiponectin synthesis and secretion.  Fasshauer et al. (2001) demonstrated β-adrenergic 
agonists inhibit adiponectin mRNA expression in 3T3-L1 adipocytes.  Other researchers 
have found similar results in human adipocytes, and found down regulation at the protein 
and mRNA levels (Delporte et al, 2002).  Glucocorticoid treatment of 3T3-L1 and human 
adipocytes also inhibits adiponectin mRNA expression (Halleux et al, 2001; Fasshauer et 
al, 2002),  and correlates with inhibition of protein secretion (Fasshauer et al, 2003).  The 
in vitro data coincide with results showing that adrenalectomized ob/ob mice have 
increased adiponectin mRNA in fat, and increased circulating plasma adiponectin 
(Makimura et al, 2002). Additionally,  adipose tissue-specific over-expression of 11β-







The pro-inflammatory cytokines highly associated with the development of 
insulin resistance also down regulate adiponectin expression.  Tumor necrosis factor-α 
inhibits adiponectin mRNA expression and protein synthesis in 3T3-L1 and human 
adipocytes (Kappes & Loffler, 2000; Maeda et al, 2001).  Also, Fasshauer et al. (2003) 
reported that treatment of 3T3-L1 adipocytes with IL-6 inhibits adiponectin mRNA 
expression and protein secretion.  This finding was substantiated by a recent report of IL-
6 as a paracrine regulator of adipose tissue.  Sopasakis et al. (2004) demonstrated a 
higher interstitial fluid concentration of IL-6 than plasma concentration, and when 
adipocytes were treated in vitro with concentrations of IL-6 found in interstitial fluid, 
adiponectin expression was inhibited. Patients who are being treated for human 
immunodeficiency virus (HIV)-associated lipodystrophy syndrome (HALS) have 
elevated levels of  TNFα, IL-6, and interleukin 8 due to the  pro-inflammatory response 
from active anti-retroviral therapy (Lihn et al, 2003).  These individuals also have 
reduced adiponectin mRNA expression and plasma adiponectin levels.   These findings 
concur with in vitro data from Bruun et al. (2003) who determined that TNFα, IL-6, and 
IL-8 in the presence of its soluble receptor inhibit adiponectin mRNA expression.  Taken 
together, it seems that pro-inflammatory responses are major regulators of adiponectin 
expression and secretion.  
Whereas pro-inflammatory cytokines regulate adiponectin expression, there 
seems to be a regulatory loop which allows adiponectin to exert anti-inflammatory effects 
on macrophages and adipocytes.  Yokota et al. (2000) were the first to report adiponectin 
exerts anti-inflammatory effects in activated human macrophages. These researchers 






macrophages.  Since these data were reported, Wulster-Radcliffe et al. (2004) determined 
that adiponectin attenuates TNFα and IL-6 production in activated pig macrophages.  Our 
lab has also found that adiponectin exerts similar anti-inflammatory effects on porcine 
adipocytes which have been stimulated with lipopolysaccharide to induce IL-6 expression 
and release (Ajuwon et al, 2004).  This information is extremely intriguing given the 
recent information linking obesity to a chronic state of inflammation, which includes a 
marked infiltration of macrophages in adipose tissue (Weisberg et al, 2003; Xu et al, 
2003).  It is thus not too far reaching to conceptualize how adipose tissue, which 
expresses and secretes inflammatory cytokines, and, an anti-inflammatory hormone could 
be a key determinant of energy balance.   
 
1.7 Metabolic functions of adiponectin 
 To date there is limited information as to the regulation of energy metabolism in 
the adipocyte by adiponectin.  Most of the metabolic studies of adiponectin have been 
focused on its relationship to insulin resistance and obesity with an emphasis on skeletal 
muscle and liver.  Some of the first clues about the metabolic effects of adiponectin were 
reports that adiponectin concentrations are lower in obese individuals and negatively 
correlated with insulin resistance (Arita et al, 1999).  This information was particularly 
interesting due to the contrast with leptin, which circulates at high concentrations during 
obesity.   
The first direct evidence for the metabolic effects of adiponectin were reported by 
Fruebis et al. (2001) who showed that adiponectin regulates lipid metabolism and body 






peptide produced by trypsin cleavage of the recombinant protein (gAdn) to identify 
metabolic implications of adiponectin.  First, mice consuming a high-fat, sucrose diet, or 
infused i.v. with a fat emulsion, had suppressed post-prandial surges in plasma 
triglyceride, free fatty acids, and glucose concentrations when infused with gAdn 
compared to control animals.  Second, fatty acid oxidation was increased in muscle 
preparations and C2C12 myotubes cultured with gAdn. Lastly, the authors examined the 
effect of adiponectin on growth and weight change in mice.  Both growing and mature 
mice were fed a high-fat, sucrose diet while body weight was monitored.  Immature mice 
infused with gAdn had suppressed weight gain verses controls, and mature mice showed 
appreciable and sustained weight loss.  This work suggests that adiponectin acts to 
promote fat utilization, rather than storage, in growing and mature rodents.   
 We recently published that adiponectin acts directly on the porcine adipocyte to 
suppress lipogenesis (Jacobi et al, 2004), and other groups have provided insight as to 
how this occurs.  Yamauchi et al. (2002) and Tomas et al. (2002) independently 
determined that adiponectin controls fatty acid oxidation and triglyceride storage in 
skeletal muscle by activation of 5’AMPK.  Activated AMPK phosphorylates acetyl CoA 
carboxylase (ACC) to deactivate it.  Inactivation of ACC allows depletion of cytosolic 
malonyl CoA, which in turn relieves the allosteric repression of carnitine 
palmitoyltransferase (CPT-1).  This enhances fatty acid transport and oxidation.  Given 
this mechanism, it seems possible that adiponectin could work similarly in adipocytes to 








1.8 Adiponectin receptors 
Understanding the mechanisms by which adiponectin functions to regulate energy 
balance and inflammation will require a delineation of how the adiponectin receptor is 
regulated.  Recently, Yamauchi et al. (2003) reported cloning of two adiponectin 
receptors, adipoR1 and adipoR2.  AdipoR1 is predominantly expressed in skeletal muscle, 
whereas adipoR2 is predominantly found in liver (Yamauchi et al, 2003). However, 
recent reports document expression of both receptors in adipose tissue and macrophages 
(Chinetti et al, 2004; Fasshauer et al, 2004).  The insulin-sensitizing effects of 
adiponectin seems to be mediated by increased fatty acid oxidation via phosphorylation 
of AMPK (Tomas et al, 2002; Yamauchi et al, 2002) and PPAR (Yamauchi et al, 2001; 
Fruebis et al, 2001; Yamauchi et al, 2003) which may be associated by regulation of the 
adiponectin receptors. 
There are currently two reports which address the regulation of these receptors in 
different physiological states.  Debard et al. (2004) reported adipoR1 and adipoR2 
expression were not altered in the muscle of type II diabetic patients compared with 
healthy subjects, and that adipoR1 was up-regulated in patients with type II diabetes 
following a 3 hour hyperinsulinemic-euglycaemic clamp.  However, Tsuchida et al. 
(2004) demonstrated insulin levels are negatively correlated with adipoR1 and adipoR2 
expression and with adiponectin sensitivity in vivo and in vitro in muscle, liver and 
adipocytes.  The down regulation of adipoR1 and adipoR2 occurs by a PI3-kinase/Foxo1 
dependent mechanism (Tsuchida et al, 2004). Through the use of binding experiments 
researchers demonstrated a down-regulation of adiponectin receptors in skeletal muscle 






ob/ob mice were infused with adiponectin (50 μg/10g body weight) the animals were 
resistant to the activation of AMPK in their skeletal muscle, suggesting that adiponectin 
resistance may occur by down-regulation of the adiponectin receptors in states of insulin 
resistance. Development of metabolic syndrome and eventually insulin resistance is 
highly correlated with chronic inflammation in adipose tissue (Xu et al, 2003).  Recently, 
Tsuchida et al. (2005) reported there is a link between adiponectin, adiponectin receptors, 
PPARs and inflammation.  They reported a novel mechanism by which there is a balance 
between activation of PPARα and PPARγ that tightly controls obesity-induced insulin 
resistance.  Their proposed mechanism begins with the activation of PPARα suppressing 
inflammation in WAT by suppressing adipocyte hypertrophy.  Second, when there is 
activation of PPARγ, as well as PPARα, the former allows for an increase in high 
molecular weight form of adiponectin and the latter allows increase adiponectin receptor 
expression in WAT.  Therefore, it would appear there is an elegant feedback system in 
adipocyte hyperplasia and hypertrophy regulated by PPAR transcription factors that 
tightly controls adiponectin, adiponectin receptors, inflammation and energy balance. 
  
1.9 PPARs and inflammation  
 The peroxisome proliferator-activated receptors (PPARs) are members of a 
nuclear receptor superfamily consisting of three different genes, PPARα, PPARβ/δ, and 
PPARγ.  All three PPARs are widely expressed; however, their relative levels differ 
greatly between tissues and are reflective of their distinct biological functions (Chinetti et 
al., 2003).  PPARs are ligand-dependent transcription factors. Some or their known 






pharmacological compounds.  The lipid lowering fibrates and the antidiabetic glitazones 
are synthetic ligands for PPARα and PPARγ, respectively (Chinetti et al., 2000).  PPARs 
influence gene expression either by activation or repression of specific 
promoter/transcription factors of targeted genes. The different isoforms play distinctive 
roles in the regulation of lipid metabolism, glucose metabolism, and cell differentiation, 
and recently have been implicated in obesity-related inflammation (Moller and Berger, 
2003).   
 The first evidence for a potential role for PPARs in inflammation came from 
Devchand et al. (1996) who observed PPARα-deficient mice have prolonged 
inflammation in response to leukotriene B4.  Interestingly, others have implicated PPARα 
as inhibitor of inflammatory molecules such as endothelin-1 intracellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells 
and tissue factor, matrix metalloproteinase (MMP)-9 and TNFα in macrophages 
(reviewed by Chinetti et al., (2000)).  Staels et al. (1998) demonstrated in human aortic 
smooth muscle cells (SMC), PPARα activation by fibrates inhibits IL-1 stimulated IL-6 
secretion and 6-keto platelet growth factor (PGF)1α production by decreasing IL-6 and 
cyclooxygenase (COX)2 gene transcription.  Additionally, splenocytes from PPARα-
deficient mice have increased IL-6 and interleukin 12 (IL-12) secretion in response to 
LPS than cells from wild-type mice (Delerive et al., 2001). With the current evidence 
demonstrating the adipocyte functions in inflammation it was not surprising when 
Tsuchida et al. (2005) showed PPARα agonist decrease inflammatory genes in WAT 
from  obese diabetic KKAy mice.  Altogether, these observations substantiate the role of 






 The role of PPARγ in inflammatory response is more controversial because the 
PPARγ null mouse is a lethal mutation (Zhu et al., 2000).  Therefore, researchers must 
use a heterozygous knockout model or a tissue specific knockout to study the genetic 
impact of PPARγ on inflammation.  Chinetti et al. (2001) demonstrated PPARγ ligands 
can inhibit mRNA abundance of TNFα, IL-6 and IL-1β in monocytes, and in 
macrophages. PPARγ ligands also suppress inducible nitric oxide synthase (iNOS) and 
MMP-9 expression and increase IL-1 receptor antagonist (Meier et al., 2002).  PPARγ 
activation also has decreased IFN-γ and IL-12 secretion in splenocytes (Cunard et al., 
2002).  Ajuwon and Spurlock (2004) demonstrated that IFN-γ suppressed the activation 
of PPARγ2 induction by adiponectin in LPS-challenged adipocytes.  These data implicate 
PPARs as a regulator of inflammation and a modulator of energy status.   
 The recent reports of chronic inflammation in WAT by macrophage infiltration 
may cause whole-body insulin resistance in obese diabetic animals (Xu et al., 2003).  
Activated macrophages that infiltrate into WAT secrete cytokines which can impair 
adipocyte insulin sensitivity.  Adipocytes stimulated by pro-inflammatory cytokines 
secrete chemokines that can contribute to macrophage infiltration.  This vicious cycle 
impairs adipocyte insulin signaling and may eventually cause system insulin resistance 
(reviewed by Fantuzzi, 2005). Moreover, inflammatory markers such as C-reactive 
protein, MCP-1, and MSF-1 are associated with insulin resistance, adiposity, and type II 
diabetes in human subjects.  Therefore, it has become important to investigate the 








1.10 Insulin resistance 
Regulation of glucose metabolism is tightly controlled in normal individuals even 
during fasting and feeding within a very narrow range.  The tight control is directed by 
the balance between glucose absorption from the intestine, production of glucose by the 
liver, uptake and metabolism by peripheral tissues.  Insulin helps modulate glucose 
concentrations by stimulating glucose uptake in muscle and fat and inhibits hepatic 
glucose production, thus serving as the principal regulator of blood glucose concentration.  
Insulin also promotes cell growth and differentiation, and enhances the storage of 
substrates in fat, liver and muscle by promoting lipogenesis, glycogen and protein 
synthesis, and inhibiting lipolysis, glycogenolysis and protein breakdown.  
Hyperinsulinemic conditions associated with insulin resistance produce an overwhelming 
dysregulation of these processes, and produces elevations in fasting and postprandial 
glucose and lipid levels.   
 Insulin stimulates glucose uptake in cells by activating a signaling cascade 
leading to the translocation of the glucose transporter, GLUT4, from intracellular vesicles 
to the cell surface.  Skeletal muscle is responsible for up to 75% of insulin-stimulated 
glucose disposal, while adipose tissue accounts for only a small portion (Klip et al., 1990).  
Despite skeletal muscle being the dominant tissue for glucose disposal the importance of 
adipose tissue is substantiated in the literature.  Mice with an insulin receptor knockout in 
muscle have normal glucose tolerance (Bruning et al., 1998), while those with a knockout 
of the insulin-sensitive GLUT4 in fat have impaired glucose tolerance, apparently due to 
induction of insulin resistance in muscle and liver (Abel et al., 2001).  Both obesity and 






demonstrating that adipose tissue is critical in regulating metabolism  (Gavrilova et al., 
2000).   
 
1.11 The insulin receptor and signaling pathways 
The insulin receptor belongs to a subfamily of receptor tyrosine kinases (Patti and 
Kahn, 1998).  These receptors are tetrameric proteins consisting of two α- and two β-
subunits that function as allosteric enzymes in which the α-subunit inhibits the tyrosine 
kinase activity of the β-subunit.  When insulin binds to the α-subunit it enables the  
kinase activity in the β-subunit followed by transphosphorylation of the β-subunits and a 
conformational change that further increases kinase activity (Patti and Kahn, 1998).   
 The signaling cascade initiated by the induction of tyrosine phosphorylation of the 
insulin receptor can activate at least nine intracellular substrates (Saltiel and Kahn, 2001).  
Four of these proteins belong to the insulin receptor substrate (IRS) family (White and 
Yenush, 1998).  Some of the alternative substrates include Gab-1, p60
dok
, Cbl, APS and 
isoforms of Shc (Pessin and Saltiel, 2000). Phosphorylation of tyrosine molecules in the 
substrates provides docking sites for proteins with Src-homology-2 (SH2) domains.  The 
SH2 containing proteins can have different functions.  They can function as adaptor 
proteins which activate further proteins in the cascade, as kinases and phosphatases 
which propagate the signaling cascade, and/or regulate their own function and subcellular 
location (Saltiel and Kahn, 2001).   
 The IRS proteins have high homology but their functions do not appear to be 
redundant but rather complimentary to each other.  In fact, mice lacking IRS-1 function 






peripheral tissues (Araki et al., 1994; Tamemoto et al., 1994).  Whereas, IRS-2 deficient 
mice have tissue specific growth retardation in the areas of the brain, islets, and retina, 
but these animals also develop peripheral tissue insulin resistance (Kido et al., 2000; 
Withers et al., 1998).  However, the IRS-3 and IRS-4 knockout mice display mild 
aberrations to near normal growth and metabolic development (Fantin et al., 2000).  The 
actual metabolic importance of IRS-3 and -4 is not well understood but there is some 
thought that IRS-3 and 4 may play a role as negative regulators of IRS-1 and 2 (Tsuruzoe 
et al., 2001).   
 The insulin receptor and insulin receptor substrates are activated by tyrosine 
phosphorylation but they can be negatively regulated by serine phosphorylation allowing 
negative feedback on insulin signaling and enabling crosstalk with other pathways which 
may be involved in the development of insulin resistance {(Saltiel and Kahn, 2001).  
Some of the key kinases implicated in this regulation are PI3K, Akt, glycogen synthase 
kinase (GSK)-3 and mammalian target of rapamycine (mTOR).  The PI3K, Akt/PKB, 
and PKC seem to play integral parts in regulation of glucose metabolism and therefore 
glycogen, lipid and protein synthesis.  Inhibition of a cell to regulate glucose and/or lipid 
metabolism has become tightly aligned with obesity and the development of related 
metabolic disorders.    
The complexities by which insulin signaling and insulin resistance are regulated 
still remain a complex story to be unraveled.  The pleiotropic condition is a combination 
of genetic and environmental factors which impact the metabolic state of a person.  There 
are different thresholds of insulin resistance and once an individual reaches a certain 






Perpetuation of this state can lead to sustained insulin insensitivity in multiple tissues of 
the body.   
The concept of excess nutrients impacting insulin sensitivity is not far reaching, 
because obesity is associated excess energy intake and there is a high correlation of 
hyperglycemia and hyperlipidemia with the development of insulin resistance.  This 
concept has been substantiated by Tang et al., (2001), who demonstrated in adipocytes a 
combination of hyperglycemia and hyperinsulinemia reduced insulin-stimulated glucose 
uptake.  The mechanism was in part due to decreased insulin receptor dephosphorylation.  
Others have also shown low and high glucose levels in 3T3-L1 adipocytes effect insulin-
mediated IRS-1 phosphorylation (Gagnon and Sorisky, 1998).  The reduced capacity of 
the cell to respond to insulin in times of nutrient excess has been linked to the 
development of reactive oxygen species (ROS) in the cell.  Lu et al. (2001) demonstrated 
rat adipocytes under hyperglycemic conditions have decreased insulin signaling and 
increase in intracellular ROS.  Additionally, adipocytes isolated from high fat diet-
induced diabetic animals have elevated intracellular ROS which can be normalized by 
incubating the cells in low glucose media (Talior et al., 2003).  In this study, there was an 
increase in basal glucose uptake, however, a reduction in insulin-stimulated glucose 
uptake.  The increase in basal glucose uptake may increase the flux of glucose through 
the aldose reductase pathway leading to elevated mitochondrial ROS and induction of 
inflammation in WAT.  This hypothesis was further investigated by Scherer’s lab (2005), 
who demonstrated 3T3-L1 adipocytes under hyperglycemic conditions have a reduced 
ability for insulin-stimulated glucose uptake.  This effect is mediated by an induction of 






to euglycemic conditions.  In addition, the researchers’ demonstrated hyperglycemia 
causes an induction of mitochondrial proteins and ROS in adipocytes.  The in vitro 
induction of ROS in adipocytes was substantiated by a pro-inflammatory response in 
animals under euinsulinemic hyperglycemic clamp condition (Lin et al., 2005).  
Interestingly, they also demonstrated lowering of the mitochondrial membrane potential 
in adipocytes can significantly reduce ROS levels.  Combined, the induction of insulin 
resistance by nutrient excess in the adipocyte is partially mediated by an increase in ROS 
that leads to an inflammatory state.    
 
1.12 Putting it together:  adipocytes, nutrient excess, inflammation and adiponectin 
Our published data provide clear evidence that adiponectin suppresses LPS-induced 
activation of the NFkB transcription factor in macrophages and adipocytes (Wulster-
Radcliffe et al., 2004; Ajuwon et al., 2004).  This is of particular interest because 
adiponectin activates AMPK in adipocytes (Wu et al., 2003), and because recent 
publications indicate that 5-amino-4-carboxamide-1-β-4-ribofuranoside (AICAR), a 
chemical activator of AMPK, disrupts LPS-induced activation of NFkB and suppresses 
pro-inflammatory cytokine production in rodent glial cells (Giri et al., 2004).  Consistent 
with these findings, AICAR also activates AMPK in human adipose explants and 
suppresses pro-inflammatory cytokine release (Lihn et al., 2004).  Consequently, the first 
objective is to determine whether adiponectin activates AMPK in adipocytes.  We 
hypothesize that adiponectin will activate AMPK, and that this activation is critical to the 






the adipocyte by inhibition of adipocyte lipogenesis and induction of oxidation in the 
cells.  
 To further the hypothesis of adipocyte energy metabolism being an integral part in 
whole body energy homeostasis the following diagram implicates the role of excess 
nutrients in perpetuating chronic inflammation during obesity.  In the following figure we 
hypothesize that over consumption of energy increases adipocyte size.  As adipocyte size 
increases, an inflammatory signal, possibly IL6, is generated to initiate a local 
inflammatory response which results in the expression of macrophage recruitment and 
maturation factors (MCP-1 and M-CSF).  As inflammation progresses, recruited 
macrophages are activated and adiponectin and/or its receptors in macrophages and 
adipocytes are down regulated, resulting in adiponectin resistance.  Thereafter, systemic 
inflammation develops, adiponectin receptors (R1 and R2) are down-regulated in skeletal 
muscle, and the ability of adiponectin to activate the AMPK is diminished.  Consequently, 











Figure 1.1 Hypothesis for the autocrine role of adiponectin in maintaining energy balance 
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CHAPTER 2.  CLONING AND EXPRESSION OF PORCINE ADIPONECTIN, AND 
ITS RELATIONSHIP TO ADIPOSITY, LIPOGENESIS, AND THE ACUTE 
PHASE RESPONSE 
2.1 Abstract 
Adiponectin is an adipocyte-derived hormone that has been implicated recently in the 
regulation of inflammation in immunocytes, and in lipid metabolism and glucose 
homeostasis in liver, skeletal muscle, and adipocytes.  However, information in non-
rodent models is limited.  We have cloned and sequenced the porcine adiponectin open 
reading frame (ORF) and evaluated the regulation of adiponectin, in vitro and in vivo.  
The porcine sequence shares approximately 88, 86, 85 and 83% homology with the dog, 
human, cow and mouse adiponectin, respectively, and 79-83% similarity with dog, 
human, cow and mouse proteins at the amino acid level, based on the translated porcine 
sequence and GenBank submissions for the other species.  Short term (4-8 hours) 
treatment of isolated pig adipocytes with the pro-inflammatory cytokines, TNF-α and IL-
6, and the β-adrenergic agonist, isoproterenol, had no effect on the abundance of 
adiponectin mRNA.  Likewise, relative serum adiponectin concentrations were not 
altered in pigs infused with E. coli, and mRNA expression in adipose tissue was not 
responsive to lipopolysaccharide.  However, analysis of serum from very lean vs. a 







concentrations are higher (P < 0.01) in lean pigs than in the fatter line, and that the 
difference is established relatively early in the growth curve.  Also, incubating pig 
adipocytes for 6 hours with recombinant pig adiponectin resulted in an approximate 30% 
reduction (P < 0.05) in lipogenesis compared with adipocytes under basal conditions and 
with those incubated in the presence of insulin. This is the first report in any species that 
adiponectin antagonizes the incorporation of glucose carbon into lipid in the adipocyte, 
and provides additional evidence that adiponectin acts as an autocrine regulatory factor to 
regulate energy metabolism.  
 
2.2 Introduction 
Adiponectin is a relatively new “adipocytokine” that circulates in the blood as the mature 
protein (Arita et al., 1999), and as an apparent carboxyl terminal proteolytic cleavage 
peptide that has marked structural similarity to tumor necrosis factor-α (Fruebis et al., 
2001).  In humans, relatively high concentrations of adiponectin (2-20 µg per mL) are 
found in the circulation (Arita et al., 1999).  Early findings indicated an anti-
inflammatory role for adiponectin.  Specifically, recombinant human adiponectin reduced 
TNF-α expression and secretion by macrophages stimulated with lipopolysaccharide, and 
also reduced their phagocytic activity and stimulated apoptosis of certain 
myeolomonocytic cell populations (Yokota et al., 2000).  Apart from the anti-
inflammatory activity, recent developments have also implicated adiponectin as a 
regulator of insulin sensitivity, glucose homeostasis and lipid metabolism.  Both intact 






muscle (Fruebis et al., 2001; Tomas et al., 2002; Yamauchi et al., 2002) and liver (Berg et 
al., 2001; Combs et al., 2001; Yamauchi et al., 2001), albeit with different potencies; 
adiponectin causes weight loss, up-regulates fatty acid transporters, and stimulates fatty 
acid oxidation in skeletal muscle, and augments the suppression of glucose production by 
insulin in the liver.  Furthermore, Wu et al. (2003) have shown a direct stimulatory effect 
of globular adiponectin on glucose uptake in primary rat adipocytes, and provided 
compelling evidence that this peptide attenuates the inhibition of insulin-stimulated 
glucose uptake by TNF-α.  Collectively, these regulatory actions across skeletal muscle, 
liver and adipose tissue would abrogate the insulin insensitivity and hyperglycemia 
common in rodent models of Type II diabetes.   
 In contrast with leptin, which is increased with body fat accretion and obesity, 
plasma concentrations of adiponectin are decreased in a number of altered metabolic 
states, including obesity (Arita et al., 1999), dyslipidemia (Matsubara et al., 2002), and 
Type II diabetes and coronary artery disease (Hotta et al., 2000).  Recently, Fruebis et al. 
(2001) hypothesized that the reduction in circulating adiponectin that is associated with 
obesity is causally related to the excessive accumulation of body fat.  Furthermore, 
Yamauchi et al. (2001) discovered that leptin and adiponectin were additive in their 
enhancement of the inhibition of glucose production by insulin in the liver of lipotrophic 
mice.  Thus, the relationship between circulating adiponectin, leptin, and adiposity in the 
pig, a rapidly-emerging research model, is of considerable interest. 
 With these considerations in mind, our primary objectives were to test the 






adipocyte, and 2) that serum adiponectin concentrations reflect differences in adiposity in 
lean vs. a fatter line of pigs, and that it is reciprocally regulated with leptin.  Also, the 
anti-inflammatory actions of adiponectin indicate that the short-term regulation of 
adiponectin may be important during the acute phase response, and may relate to the 
regulation of metabolism and immune response pathways by pro-inflammatory cytokines.  
Consequently, our third objective was to determine whether serum adiponectin or mRNA 
expression is altered by bacterial infection or endotoxin challenge, and to determine 
whether specific cytokines act acutely on the adipocyte to regulate adiponectin mRNA 
abundance. 
 
2.3 Materials and Methods 
Animals and adipocyte isolation 
 Adipose tissue was obtained from male castrates weighing approximately 90-110 
kg, and consuming a nutritionally-complete diet ad libitum.  The pigs were maintained 
according to protocols approved by the Purdue University Animal Care and Use 
Committee, and killed in the Purdue University abattoir according to USDA regulations.  
Subcutaneous adipose tissue was removed from the dorsal depot located over the cervical 
spine, and transported in buffered saline (37
o
C, 0.15 M NaCl, 10 mM HEPES, pH 7.4) to 
the laboratory.  Adherent skeletal muscle was removed, and the tissue was cubed and 
sliced with a Stadie-Riggs microtombe.  Approximately 6-7 g of sliced tissue was 
minced, rinsed with saline, and transferred to a flask containing 15 mg collagenase (100 






30-35 minute digestion period, isolated adipocytes were washed through a 290 μm screen 
with warmed Krebs Ringer bicarbonate buffer (pH 7.4) containing 10 mM HEPES, 5 mM 
glucose, and 3% bovine serum albumin (Fraction V, essentially fatty acid free, Invitrogen 
life technologies, Carlsbad, CA USA) to remove all other cell debris.   The cells were 
resuspended in culture media (DMEM Sigma D6780; St. Louis, MO USA) with 3% BSA 
and 10 mM HEPES at a final concentration of approximately 2 x 10
5 
cells per mL and 
aliquoted immediately into 15 mL polypropylene scintillation vials for incubation.   
RNA isolation 
 Total RNA was extracted from cells as described by Chomczynski and Sacchi 
(1987).  Briefly, cells were homogenized in guanidium thiocyanate, followed by the 
addition of sodium acetate.  The samples were then extracted sequentially with water-
saturated phenol and chloroform:isoamyl alcohol, and the aqueous fractions precipitated 
with isopropanol.  After the second ethanol precipitation, the RNA pellets were 
resuspended in Tris-HCl buffer (pH 8.0) and quantitative and qualitative measures 
obtained spectrophotometrically.  In addition, the actual RNA concentration of sample 
was determined using the RiboGreen® assay (Molecular Probes, Eugene, OR USA) and 
the manufacturer’s protocol.   
Cloning 
 Degenerative primers from highly conserved regions of mouse and human 
adiponectin sequences were designed to amplify porcine adiponectin cDNA using long 
distance PCR (forward primer: 5’-CTGTCAATTTCAGGGCTCAGG-3’; reverse primer: 






amplifying a reverse-transcribed product of RNA extracted from isolated adipocytes from 
90 kg pigs. A cDNA clone of about 1100 bp contained a 732 bp open reading frame 
coding a 243 amino acid protein.   The 1100 bp product was cloned into the PCRII-
TOPO vector (Invitrogen life technologies; Carlsbad, CA USA) for sequencing.   
Protein expression and purification  
 The protein expression and purification was carried out in a commercial facility 
(C&P Biotech Corp.,Thornhill, Ontario, Canada).  Briefly, DNA containing the coding 
region of mature porcine adiponectin was amplified by PCR, then subcloned into pET15b 
(Novagen; Madison, WI USA) sites (NdeI, and BamHI/BglII) to introduce an N-terminal 
His-tag and thrombin cleavage site.  Once the insertion of the gene was verified by DNA 
sequencing, the plasmid was transformed into BL21 (DE3) cells (Stratagene; La Jolla, 
CA USA).  The cells were grown in LB broth with 50 µg per mL of ampicillin in shaker 
flasks at 37
o
C, 200 rpm, until the OD600 was 0.7.  Thereafter, 1 mM IPTG was added for 
induction, and after two hours, the cells were harvested by centrifugation at 5,000 rpm for 
15 minutes, and stored at –80o C.  The cells were lysed in 50 mM Tris pH 8.0, 500 mM 
NaCl, 1 µM phenylmethysulfonyl fluoride (PMSF), and sonicated with power level 8, 
30% duty cycle for 3 minutes with a Sonifer brand sonicator (VWR International; Bristol, 
CT USA).  The supernatant fraction from the lysate was harvested by centrifugation at 
15,000 rpm for 30 minutes, and it was loaded onto a Ni-NTA agarose column (Qiagen; 
Valencia, CA USA).  The column was washed with 50 mM Tris pH 8.0, 500 mM NaCl, 
10 mM immidazole, and then the protein was eluted with 250 mM immidazole in the 
same buffer.  Fractions containing the protein of interest were pooled and dialyzed 
overnight at 4
o






Thrombin (Calbiochem; San Diego, CA USA) per mg of protein.  The protein sample 
was further purified over an S75 column (Amersham Pharmacia Biotech; Piscataway, NJ 
USA) with PBS to remove the thrombin and His-tag. The fractions containing the protein 
were pooled and dialyzed into PBS overnight.  Prior to use, the recombinant protein was 
concentrated by evaporative drying.  Amino terminal sequencing of the recombinant 
protein was carried out to confirm the identity of the expressed protein. The globular 
domain was cloned and expressed similarly.  Amino terminal sequencing of this peptide 
confirmed its identity. The N-terminal sequence of the recombinant cleavage product was 
obtained to confirm the identity of the expressed peptide.  Endotoxin analysis was 
performed by a commercial laboratory (Cambrex Inc., Walkersville, MD USA) to verify 
the purity of the preparation. 
Northern analysis and treatments 
Total RNA was extracted as described above from isolated adipocytes which were 
incubated for 4 and 8 hours under 5% CO2- 95% air with the following treatments: basal 
control, 10 ng/mL TNF-α, 10 ng/mL IL-6 and 10-6 M isoproterenol.  Adiponectin mRNA 
was measured by Northern blot analysis with a porcine adiponectin cDNA corresponding 
to a ~320 bp region from the ORF of porcine adiponectin.  The porcine adiponectin 
cDNA template was obtained by reverse transcription-polymerase chain reaction (RT-
PCR) procedures, and the PCR product was confirmed by sequence analysis.  The 
antisense primer of adiponectin was added to the T7 promoter sequence (5’-
GGATCCTAAT ACGACTCACT ATAGGGAGG-3’) to allow northern probe 
transcription under the control of T7 polymerase.  Radiolabeling of the probe was 








UTP (NEN/Perkin Elmer; Boston, MA USA).  The probe was gel purified on a 5 % 
acrylamide-8 M Urea gel and eluted from gel with probe elution buffer (Ambion; Austin, 
TX USA) overnight.  Northern blots were performed with 3 μg of total adipocyte RNA.  
Samples were transferred to nitrocellulose membranes (Perkin Elmer Life Sciences Inc., 
Boston, MA USA) cross-linked with UV light and baked for 2 hours at 80
o
C.  
Membranes were probed overnight, washed and exposed to x-ray film overnight.  
Autoradiographs were quantitated by image analysis.  Following autoradiography, the 
membranes were stripped in .1 X SSC (1.5 M NaCl, .15 M sodium citrate, pH 7.0), .5% 
SDS at 95
o
C to remove probe and rehybridized with a RNA probe corresponding to 18S 
rRNA.  The abundance of the 18S rRNA was used to standardize adiponectin mRNA 
abundance.   
Lipogenesis 
 For lipogenic determinations, six 2-mL aliquots of cell suspension were added to 
15 mL of polypropylene scintillation vials, gassed with 5% CO2- 95% air and incubated 
for 6 hours at 37
o
C in an environmentally controlled shaking incubator.  Cells were 
treated with no hormone, 30 μg/mL full length porcine adiponectin, 30 μg/mL cleaved 
porcine adiponectin or 1 mU/ml porcine insulin (Sigma I- 5532; St. Louis, MO USA).  
Vials also contained 0.75 μCi [U-14C]-glucose (NEN/Perkin Elmer; Boston, MA USA) 
and incubation media was the same as described above.  After the appropriate incubation 
periods, the reactions were terminated with the addition of 100 μl 17% perchloric acid.  
Total lipid was extracted with Dole’s reagent.  Briefly, 5 mL of Dole’s reagent, 3 mL 
hexane, and 4 mL distilled H2O were added and mixed in each vial.  The phases were 
allowed to separate and the upper phase recovered and evaporated at 70
o






Thereafter, 5 mL scintillation cocktail was added to vials the counts determined for 
calculation of lipogenic activity.   
SDS-PAGE and Immunoblotting 
 Sample proteins were separated by discontinuous SDS-PAGE (Laemmli, 1970) 
using a 3.75% stacking gel and 12.5% resolving gels and then transferred to 
nitrocellulose membranes.  For all experiments in which serum adiponectin was 
quantified on a relative basis, the adiponectin protein was detected using a monoclolnal 
anti-human adiponectin antibody (ANOC 9108) which has been described previously 
(Okamoto et al., 2000; Ouchi et al., 2000).  Preliminary experiments established a range 
of dilutions for pig serum (1:5 to 1:40) over which adiponectin signal intensity was linear 
with our colorimetric detection system and image analysis.  Furthermore, the antibody 
was validated for use with pig serum by competitive displacement of signal when a range 
of antibody dilutions (1:1000 to 1:20,000) were preincubated with an excess of 
recombinant pig protein.   Colorimetric visualization was accomplished via alkaline 
phosphatase-linked secondary antibody (goat anti-mouse IgG; American Qualix; La 
Mirada, CA), which was used at a dilution of 1:2,000.  Western blotting with the 
monoclonal antibody indicated a primary band at approximately 30 kDa.  This band was 
quantified as adiponectin in all experiments based on the fact that the antibody is 
monoclonal and binds recombinant pig adiponectin, and on our determination that the 









 To determine whether relative serum adiponectin concentrations reflect the 
differences in body fat in lean vs. a fatter genotype of pigs, two genetic lines were 
compared across several ages.  The pigs were maintained, and killed at the appropriate 
time, according to a protocol approved by the Purdue University Animal Care and Use 
Committee.  Females were housed in individual pens and allowed ad libitum intake of 
diets that were nutritionally complete with respect to the age of the pig.  Actual body 
weight was recorded and measures of subcutaneous backfat depth were taken at the 10
th
 
rib approximately 2 cm off the midline in the pigs killed at the selected time points (28, 
56, 90 and 165 days of age).  Relative serum adiponectin concentrations were determined 
by western blot analysis with the monoclonal antibody as described above.  Additionally, 
serum leptin was quantified by a pig-specific RIA that is based on a polyclonal antibody 
generated against a synthetic peptide designed per the amino acid sequence derived from 
translation of the pig leptin ORF, as we have reported previously (Bidwell et al., 1997).  
The peptide (LQGALQDMLRQLDLSPGC) was complexed to keyhole limpet 
hemocyanin and used to immunize rabbits.  The antibody was affinity purified, validated 
by western blot analysis of recombinant pig leptin and pig serum, and used for the RIA of 
serum leptin.  Recombinant pig leptin (4 μg) was radiolabeled (125-I) using Chloramine-T 
and a 22 second reaction period.  For the RIA, 200 µL samples were assayed in duplicate.  
The range of accurate quantification was from 0.25 to 16 ng per mL.  Excellent 
regression was obtained from 94% to 7% binding (based on the 0 standard), and the 
standard curve has excellent correlation (0.99) over the range of 0-16 ng leptin per mL.  






leptin) that was added to a pooled internal standard averaged 112.8%, well within the 
acceptable range.  Parallelism was confirmed by assaying different volumes of a pooled 
internal serum standard (25, 50, 100, 150 and 200 µL per tube) which produced 
concentration estimates that were acceptably similar (coefficient of variation of 11.4%).  
The intra- and inter-assay coefficients of variation were 9.7% and 11.6%, respectively.  
The data were analyzed using a mixed model analysis which tested the effects of genetic 
line and age, and the interaction of line and age.  Mean comparisons were established 
using the pdiff procedure of SAS when protected by a significant F-test.   
E. coli challenge 
 The pigs used in this study were obtained from a commercial genetics 
company (Pig Improvement Company, Inc., Franklin, KY) and housed at the Purina 
Mills, Inc. Research Center, Gray Summit, MO.  The protocol was approved by the 
corporate animal care and use committee.  Briefly, individually-penned pigs (male 
castrates weighing approximately 70 kg) were allotted to 3 treatment groups consisting of 
a control group that was allowed ad libitum feed intake, a feed-deprived group, and a 
group deprived of feed and infused i.v. with an E. coli isolate (5 X 10
9
 cfu) that was 
cultured from pig feces and provided by the Veterinary Services Department, Purina 
Mills, Inc., St. Louis, MO.  The control and feed-deprived groups were infused i.v. with 
the same volume (10 mL) of sterile medium used to deliver the E. coli to the challenged 
group.  Blood samples were obtained by jugular venipuncture from all pigs just prior to 
infusion, and at 6, 12 and 24 hours following infusion.  Feed consumption and rectal 
temperatures were obtained at the time of blood sampling to confirm the induction of an 






concentrations were assessed by western blot analysis as described above and the data 
quantified by image analysis.  Statistical analysis was performed using a mixed model 
analysis in which the effects of time (age) and treatment were tested, as was the 
interaction of time and treatment.   
 
2.4 Results 
Cloning of porcine adiponectin ORF 
 Using RT-PCR and adipocyte RNA, we cloned the porcine adiponectin ORF.  
The resulting nucleotide sequence, aligned with available sequences from selected 
species, is shown in Figure 2.1A, and the translated amino acid sequence is presented in 
Figure 2.1B.  The ORF for porcine adiponectin was determined to be 732 bp in length, 
and when translated, yields a protein of 243 amino acids.  The identity between the 
porcine nucleotide sequence and the rhesus monkey, human, dog, cow, mouse and rat is 
86, 86, 88, 85, 83, and 82 percent, respectively (Table 2.1), and at the amino acid level, 
the identity was 79-83%, based on the GenBank translations of the mouse, cow, human, 
and monkey adiponectin sequences.  Northern blot analysis of adiponectin expression in 
adipose tissue and isolated adipocytes is shown in Figures 2.2A and B, respectively.  In 
adipose tissue, we detected a predominant transcript of approximately 3.0 kb, and 
transcripts of much lesser abundance at approximately 1.7, 1.3, and .9 kb.  In isolated 
adipocytes, the three smaller transcripts are absent, with the exception of one pig in 






were detected.  Using Northern blot analysis and RT-PCR, we also confirmed that 
adiponectin expression is limited to the adipose tissue of the pig (data not shown). 
 Western blot analyses of pig serum with the monoclonal anti-human adiponectin 
antibody indicated the presence of two major proteins of approximately 30 and 35 kDa 
(Figure 2.3).  The most abundant 30 kDa protein is similar in size to the single band 
detected by the antibody in control human serum, and the less abundant, 34-35 kDa 
protein is similar that reported previously for mice (Yoda-Murakami et al., 2001).   
Anti-lipogenic effect of adiponectin on porcine adipocytes 
 The effect of adiponectin on lipogenesis and lipolysis were measured in isolated 
adipocytes in six-hour incubations.  Basal and insulin-stimulated lipogenesis, which were 
based on the incorporation of labeled glucose into extractable lipid, were reduced 28% 
and 30%, respectively, (P < 0.05) by the full-length recombinant adiponectin (Figure 
2.4).  However, the recombinant molecule representing the apparent cleavage peptide was 
ineffective at the same concentration (i.e., 30 μg per mL).  Neither the intact protein nor 
cleavage peptide altered lipolysis, as assessed based on glycerol release from incubated 
adipocytes (data not shown). 
Regulation of serum adiponectin and mRNA expression in vivo and in vitro 
 The northern blot analyses of adiponectin expression in the in vitro adipocyte 
experiments are summarized in Figure 2.5.  The abundance of adiponectin mRNA in 
adipocytes incubated for 4 or 8 hours with 10 ng per mL of TNF-α or IL-6, or 10-6 M 
isoproterenol, was not influenced by either pro-inflammatory cytokine, or by 






infused i.v. with an E. coli isolate to induce septicemia (Figure 2.6).  The latter finding 
was confirmed at the mRNA level using E. coli-derived lipopolysaccharide to mimic 
infection.  In these pigs, the abundance of the adiponectin was not changed 6 hours after a 
second injection of LPS that was administered 12 hours after the initial injection, despite 
the induction of a transient febrile response and obvious sickness behavior.  It is also 
notable that exogenous leptin did not alter the expression of adiponectin in pig adipose 
tissue (P > 0.5), whether administered alone or in combination with the 
lipopolysaccharide (data not shown).   
Serum Adiponectin and Leptin in Lean vs. Fatter Lines of Pigs 
 Serum samples were collected from pigs of two genetic lines with very different 
potentials for fat accretion, and subjected to western blot analysis.    As shown in Figure 
2.7A, relative serum adiponectin concentrations were similar in samples collected at 28 
and 56 days of age.  However, by 90 days of age, differences in adiposity (backfat depth, 
Figure 2.7B) were reflected in serum adiponectin concentrations, with the leaner pigs 
having less backfat but higher (P < 0.05) relative adiponectin concentrations at 90 and at 
165 days of age.  In contrast, serum leptin concentrations were lower (P < .01) in the lean 
line by 56 days of age (data not shown), and the magnitude of the difference between 
lines increased with time (Line X Time, P < .01).  Identical differences were detected in 










 Herein we report for the first time the sequence of the porcine adiponectin ORF, 
and provide the amino acid sequence of the protein inferred from translation of the 
nucleotide sequence.  Both the coding region and the inferred amino acid sequence share 
substantial homology with those of other species. The adiponectin transcript in pig 
adipocytes is approximately 3.0 kb, whereas there are three additional transcripts faintly 
detected in pig adipose tissue.  Other publications have documented the presence of three 
similar transcripts in rat adipose tissue (Bensaid et al., 2003; Hu et al., 1996), whereas 
mouse adipose tissue expresses a single transcript (Hu et al., 1996).  The identities of the 
smaller, lesser abundant transcripts are not known.   
 Also consistent with previous findings (Scherer et al., 1995), the mRNA for 
adiponectin seems to be limited to the adipose tissue (adipocytes) of pigs.  Although 
others have reported that adiponectin expression is induced in the liver of mice exposed 
to carbon tetrachloride, and in HepG2 cells cultured with IL-6 (Yoda-Murakami et al., 
2001), we did not detect adiponectin mRNA in the liver of pigs injected with 
lipopolysaccharide (Northern blot analysis), or in primary pig hepatocytes stimulated 
with IL-6, even using RT-PCR (unpublished observations).  A monoclonal anti-human 
adiponectin antibody detected proteins of approximately 30 and 35 kDa in pig serum.  
This smaller (30 kDa) protein is similar in size to the single protein detected in human 
serum by the monoclonal antibody, and was quantified in all experiments for which 







 Understanding the regulation of adiponectin expression in the adipocyte is central 
to understanding the relationship of this protein to inflammation, metabolism, and insulin 
sensitivity.  Previous publications (Bruun et al., 2003; Fasshauer et al., 2003; Kappes and 
Loffler, 2000) indicated that both TNF-α and IL-6 alter the expression or secretion of 
adiponectin from adipocytes (or adipose explants) in vitro. In our experiments, neither 
cytokine altered the relative adiponectin mRNA abundance.  However, the duration of 
our experiments (8 hours or less) was shorter than that used for other model systems 
described in the publications cited above.  Fasshauer et al. (2003) showed that IL-6 acted 
within 8 hours, and was apparently not dependent on the presence of its soluble receptor, 
as it was in human adipose explants (Bruun et al., 2003).  It is possible that adiponectin 
mRNA abundance would have been reduced in pig cells had we added the soluble IL-6 
receptor, but we believe it likely that the pig adipocytes require a longer duration of 
cytokine exposure for changes in adiponectin mRNA abundance to occur.  A similar 
explanation for the lack of a response to the β-agonist (i.e., reduced mRNA expression in 
response to isoproterenol) seems plausible. 
 Yokota et al. (2000) provided convincing evidence that adiponectin acted directly 
upon macrophages to attenuate pro-inflammatory cytokine (TNF-α) expression and 
secretion into the medium, and to antagonize phagocytosis.  Accordingly, we 
hypothesized initially that the acute regulation of adiponectin by inflammatory mediators 
in vivo would be such that transient increases in expression and secretion of adiponectin 
would potentiate its anti-inflammatory and metabolic actions by increasing the circulating 
protein concentration. In the lipopolysaccharide and E. coli infusion models that we used, 






and Webel et al. (1997) and Carroll et al. (2003) reported that the TNF-α, IL-6, and 
cortisol responses to lipopolysaccharide injection in the pig are relatively acute (i.e., peak 
within 4-6 hours).  Thus, our collective results at the mRNA and serum protein level 
indicate that the expression and secretion of adiponectin are not acutely regulated in vivo 
to alter the circulating protein concentration during infection.  Given the transient nature 
of the increases in the circulating concentrations of pro-inflammatory cytokines caused 
by these challenges in the pig (Webel et al., 1997), this finding in vivo is consistent with 
the absence of an effect of  TNF-α and IL-6 in adipocytes exposed in vitro, as discussed 
above.  Recently, Tsao et al. (2002) determined that the oligomerization state of 
adiponectin regulates the biological activity and effective concentration of adiponectin.  
Consequently, it seems likely that the anti-inflammatory activity of adiponectin is 
controlled through oligomerization, rather than through alterations in expression and 
secretion.   It will also be of considerable importance to determine whether either of the 
adiponectin receptors identified by Yamauchi et al. (2003) are regulated in immune cells 
or peripheral tissues during the innate immune response. 
 Both adiponectin and the cleavage peptide regulate body weight and energy 
metabolism in skeletal muscle (Tomas et al., 2002, Yamauchi et al., 2002) and liver 
(Berg et al., 2001, Yamauchi et al., 2001), albeit with different potencies.  Furthermore, 
Arita et al. (1999) determined that circulating adiponectin concentrations are lower in 
obese individuals, and in association with non-insulin-dependent diabetes, than in 
individuals with normal body composition and insulin sensitivity.  Others have recently 
confirmed this finding in adolescent obesity (Weiss et al., 2003).  We have extended 






concentrations also reflect adiposity in the pig, a rapidly emerging biomedical research 
model, and that the lower serum adiponectin in the fatter line coincides with marked 
increases in serum leptin and in leptin mRNA in adipose tissue.  This is of particular 
interest because the ratio of leptin to adiponectin has recently been proposed as an index 
of obesity in monkeys (Chen et al., 2003), and may have similar utility in other animal 
models.  Secondly, we have shown for the first time in any species that intact adiponectin 
acts directly upon the adipocyte to suppress lipogenesis.  Collectively, these findings 
support the hypothesis advanced by Fruebis et al. (2001) that the lower concentration of 
adiponectin observed in obese individuals is causally related to the excessive lipid 
accumulation.  It is also notable that leptin administration did not alter the expression of 
adiponectin, despite the substantial increase (3-fold) in circulating leptin that is achieved 
within 24 hours using the injection regimen and dose of leptin used in this study (Ajuwon 
et al., 2003).  Although not the primary objective of this experiment, to our knowledge, 
this is the first experiment to evaluate the regulation of adiponectin mRNA abundance by 
leptin.   
 It is potentially of considerable importance that adiponectin reduced lipogenic 
activity in incubated adipocytes.  It should be noted that the response of pig adipocytes to 
insulin is typically small (Mills, 1999) versus other species, and that adiponectin reduced 
lipogenic activity relative to both basal and insulin-stimulated conditions.  As regards the 
potential mechanism by which intact adiponectin regulates lipogenesis, recent findings 
are quite pertinent.  Yamauchi et al. (2002) and Tomas et al.(2002) reported that 
activation of the 5’-AMP-activated protein kinase (AMPK) is central to the regulation of 






muscle.  More recently, Wu et al. (2003) reported that globular adiponectin stimulated 
glucose transport in primary rat adipocytes cultures.  This response was dependent upon 
the activation (phosphorylation) of the AMPK, and was independent of critical factors in 
the insulin signaling pathway, including IRS-1 or Akt.  Additionally, the increased 
activity of the AMPK caused a deactivation of acetyl Co-A carboxylase, which would be 
expected to attenuate lipogenic activity.  In our experiments, the cleavage peptide did not 
reduce lipogenesis, as did the intact protein.  It is possible that our recombinant cleavage 
peptide is less biologically active, and that higher concentrations are required to suppress 
lipogenesis.  
 In summary, we have confirmed herein that relative circulating adiponectin 
concentrations reflect differences in adiposity in the pig, and report for the first time that 
adiponectin acts directly upon isolated pig adipocytes to attenuate lipogenesis.  Thus, the 
regulation of fat accretion by adiponectin may also include the direct regulation of de 
novo lipogenesis in the pig adipocytes.  The mechanism by which adiponectin regulates 
lipogenesis, and the mechanisms which culminate in lower concentrations of adiponectin 
in obese individuals may offer new targets for alleviating obesity.  We have also shown 
that adiponectin is not acutely regulated by pro-inflammatory cytokines, in vitro, or 
during the acute phase response in vivo.  These findings indicate that the anti-
inflammatory actions of adiponectin are not regulated by transient changes in expression 
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Table 2.1 Identity of porcine adiponectin compared to other species. 




Species Nucleotide % identity Amino Acid % Similarity 
Dog 88 --- 
Human 86 83 
Rhesus Monkey 86 83 
Cow  85 81 
Mouse 83 79 




















Figure 2.1.  Nucleotide sequence and translation of porcine adiponectin.  
 (A)  Comparison of porcine adiponectin (Adn) nucleotide sequence with human 
(NM_004797 gi4757759), monkey (AF404407 gi15213855), and mouse (BC028770 gi 
20381158). The percent identity of porcine nucleotide sequence with that of the species 
noted above is reported in Table 1.  B:  The translated amino acid sequence of porcine 
Adn is compared with the translated human (NM_004797 gi4757759), monkey 
(AF404407 gi15213855), mouse (BC028770 gi 20381158) and bovine (NP_777167 
gi27807433). (B) The amino acid sequence contains the predicted 18 amino acid 
secretory signal sequence, a series of Gly-X-Y repeats and a 36 amino acid region that is 
homologous to collagen VIII, collagen X, and the C chain of C1q.  The percent amino 














Figure 2.2.  Northern blot analysis of adiponectin mRNA in pig adipose tissue  
(A) and isolated adipocytes (B).  Total RNA was extracted from the adipose tissue or 
adipocytes isolated from the adipose tissue of multiple pigs; 5 µg (adipose tissue) or 2.5 
µg (adipocytes) total RNA were probed on the Northern blot with the pig-specific 
adiponectin riboprobe as described in the methods.  Different pigs were used for adipose 
tissue vs. adipocytes.  The results indicate a predominate transcript for pig adiponectin 
that is approximately 3 kb in size.  This transcript was used to establish relative 
differences among treatments in subsequent experiments.  The specificity and origin of 











Figure 2.3 Western blot analysis of pig serum using a monoclonal anti-human 
adiponectin antibody described previously (ANOC 9108; 19, 20).   
The serum samples were diluted 1:25.  Lane 1 contained the BioRad Rainbow molecular 
weight markers (not visible in image of blot) and lane 2 is a human serum control.  Lanes 
3-6 are samples from individual pigs.  The antibody detected a single predominant 
protein in human and pig serum at approximately 32 and 30 kDa, respectively, and also 
detected a larger protein of approximately 34-35 kDa in the serum of 3 pigs (Lanes 4-6), 
as was reported previously for mice (Yoda-Murakami et al., 2001).  (B) The 30 kDa band 
was quantified in pig serum samples by western blotting and image analysis as describe 










Figure 2.4.  Regulation of lipogenesis in isolated pig adipocytes by recombinant pig 
adiponectin. 
  Isolated pig adipocytes were incubated with porcine insulin (1 mU/mL), recombinant 
porcine globular adiponectin (gAdn, 30 g/mL), or recombinant full-length porcine 
adiponectin (Intact Adn, 30 µg/mL).  Cells were incubated in medium containing 0.75 
Ci/2 mL 14C-glucose for 6 h, followed by extraction of total lipids.  The data are 
expressed as a percentage of the basal treatment and represent 5 experiments performed 
with adipocytes isolated from different pigs.  The asterisk indicates significant difference 










Figure 2.5 Expression of adiponectin mRNA in isolated pig adipocytes treated with 
selected pro-inflammatory cytokines and isoproterenol 
Isolated pig adipocytes were incubated for 4 or 8 hours with 10 ng/ml of TNF-α or IL-6, 
or 10-6 M isoproterenol.  The data are standardized with 18s rRNA and represent 6 
experiments performed with adipocytes isolated from different pigs.  There was no 
significant effect of the proinflammatory cytokines or isoproterenol on adiponectin 










Figure 2.6.  Relative serum concentrations of adiponectin in pigs challenged with an i.v. 
infusion of E. coli 
Individually-penned pigs (male castrates weighing approximately 70 kg) were allotted to 
3 treatment groups (n = 9) consisting of a control group that was allowed ad libitum feed 
intake (AL), a feed-deprived group (FR), and a group deprived of feed and infused i.v. 
with 5 X 109 cfu of a fecal E. coli isolate (E. coli). The AL and FR groups were infused 
i.v. with the same volume (10 mL) of sterile medium used to deliver the E. coli to the 
challenged group.  Blood samples were obtained by jugular venipuncture from all pigs 
just prior to infusion and at 6, 12 and 24 hours following infusion.  There was no 














Figure 2.7 Relative serum adiponectin concentrations (A) subcutaneous backfat thickness 
(B) in a lean vs. a fatter genotype of pigs. 
At the ages (days) indicated, serum samples and measures of subcutaneous backfat depth 
were obtained from pigs (n = 4-5) representing the 2 genetic lines with greatly different 
potentials for fat accretion.  The asterisks indicate significant differences (P < .01) with 
respect to genotype.  Additionally, there was an interaction between genotype and age 
such that the difference in back fat depth between lines increased with age (P < .01).   
Serum leptin was determined using a pig-specific RIA as detailed in the methods.  The 
asterisks indicate significant differences (P < .01) with respect to genotype (n = 4-5).  
There was also an interaction between genotype and time in that the magnitude of the 


























































































CHAPTER 3. ADIPONECTIN REGULATES THE EXPRESSION OF GENES 
ASSOCIATED WITH FATTY ACID SYNTHESIS AND OXIDATION IN 
PRIMARY PIG ADIPOCYTES 
3.1 Abstract 
Adiponectin has been implicated in the regulation of glucose uptake and fatty acid 
synthesis in adipocytes, and in the long-term suppression of weight gain when over-
expressed in rodents by adenovirus associated virus vectors.  The aim of this research 
was to determine whether adiponectin regulates the expression of genes associated with 
fatty acid oxidation in porcine adipocytes.   Primary adipocytes were isolated from the 
dorsal subcutaneous adipose tissue of pigs (male castrates, n=5).  Cells were incubated in 
DMEM with 3% BSA, in the presence and absence of recombinant porcine adiponectin 
(30 μg/mL), and were harvested at 0, 30, 60, 120, 240 and 360 minutes.  Total RNA was 
extracted for cDNA synthesis, and the abundance of selected transcripts determined by 
real time PCR analysis.  Adiponectin transiently increased (2-6.5 fold, P < .05) the 
expression of acetyl Co-A carboxylase (ACC), AMP activated kinase (AMPK), acyl Co-
A oxidase (ACO) and peroxisome proliferator activated receptor-α (PPARα).  After the 
initial increase in mRNA abundance, there was either a return to initial levels of 
expression (PPARα), a significant reduction (AMPK), or a cyclic pattern of expression 
(ACC, ACO).  The abundance of the uncoupling protein-3 (UCP3) transcript was not 







increased 3.8-fold (P < .05).  Collectively, these data indicate that adiponectin acts 
through autocrine/paracrine signaling pathways to coordinately regulate lipid metabolism 
in the adipocyte, and may thus be a determinant of adipocyte size and overall lipid 
accumulation. – Funded by USDA 
 
3.2 Introduction 
There are striking similarities in pigs and humans in the development of certain 
physiological conditions related to cardiovascular disease, hyperglycemia, dyslipidemia, 
and insulin resistance (Gerrity et al., 2001; Otis et al., 2003).  These similarities 
underscore the potential for the pig as a research model, and also emphasize the need to 
understand cellular signaling pathways and inter-tissue communications in the pig.   
 Historically, adipocytes were seen as a passive energy storage depot.  However, it 
is now clear that white adipose tissue (WAT) synthesizes and secretes an array of 
adipocytokines which have been implicated in whole body energy homeostasis (Kahn et 
al., 2005).  Adiponectin, a relatively new adipocytokine, was cloned in the mid-1990s and 
has since been identified as a significant determinant of insulin sensitivity, glucose 
homeostasis, and lipid metabolism  (Hu et al., 1996; Maeda et al., 1996; Nakano et al., 
1996; Scherer et al., 1995).   
To date there is limited information as to the mechanisms by which adiponectin 
regulates energy metabolism in the adipocyte.  Most metabolic studies of adiponectin 
have focused on relationships among adiponectin, insulin resistance and obesity, with the 
emphasis on skeletal muscle and liver.  Fruebis et al. (2001) provided the first evidence 







have confirmed this and linked adiponectin to improved clearance of circulating free fatty 
acids, glucose and triglycerides, and suppression of hepatic glucose production (Berg et 
al., 2001; Combs et al., 2001; Fruebis et al., 2001; Yamauchi et al., 2001).   
 Yamauchi et al. (2002) and Tomas et al. (2002) independently provided evidence 
that adiponectin regulates fatty acid oxidation and triglyceride storage in skeletal muscle 
by activation of 5’AMP-activated protein kinase (AMPK).  Activated AMPK 
phosphorylates acetyl CoA carboxylase (ACC) and deactivates this enzyme to allow 
depletion of cytosolic malonyl CoA and relieve the allosteric repression of carnitine 
palmitoyltransferase (CPT-1).  Consequently, mitochondrial fatty acid transport and 
oxidation are increased. We recently published that adiponectin works directly on porcine 
adipocytes to suppress lipogenesis (Jacobi et al., 2004), and Wu et al. (2003) determined 
that rat adipocytes treated with globular adiponectin have increased Thr-172 
phosphorylation of AMPK and increased Ser-79 phosphorylation of ACC in acute (2 h) 
cultures.  It seems possible that adiponectin could work to modulate hypertrophy of fat 
cells by regulating lipid metabolism via similar mechanisms. 
Predicated on the literature cited above, the first aim of this study was to test the 
hypothesis that adiponectin acts in autocrine/paracrine fashion in porcine adipocytes to 
modulate lipogenic activity by activation of AMPK and deactivation of ACC.  The 
second aim was to determine whether adiponectin targets PPARα expression and other 
genes involved in fatty acid oxidation, and finally, to identify specific regulators of 









3.3  Methods 
Animals and adipocyte isolation 
Adipose tissue was obtained from male castrates weighing approximately 90-110 kg, and 
consuming a nutritionally-complete diet ad libitum.  The pigs were maintained according 
to protocols approved by the Purdue University Animal Care and Use Committee, and 
esanguinated in the Purdue University abattoir according to USDA regulations.  
Subcutaneous adipose tissue was removed from the dorsal depot located over the cervical 
spine, and transported in buffered saline (37
o
C, 0.15 M NaCl, 10 mM HEPES, pH 7.4) to 
the laboratory.  Adherent skeletal muscle was removed, and the tissue was cubed and 
sliced with a Stadie-Riggs microtombe.  Approximately 6-7 g of sliced tissue was 
minced, rinsed with saline, and transferred to a flask containing 15 mg collagenase (100 
U/mL final concentration; Worthington BioChemical, Lakewood, NJ USA).  Following a 
30-35 minute digestion period, isolated adipocytes were washed through a 290 μm screen 
with warmed Krebs Ringer bicarbonate buffer (pH 7.4) containing 10 mM HEPES, 5 mM 
glucose, and 3% bovine serum albumin (Fraction V, essentially fatty acid free, Invitrogen 
life technologies, Carlsbad, CA USA) to remove all other cell debris.   The cells were 
resuspended in culture media (DMEM Sigma D6780; St. Louis, MO USA) with 3% BSA 
and 10 mM HEPES at a final concentration of approximately 2 x 10
5 
cells per mL and 
aliquoted immediately into 15 mL polypropylene scintillation vials for incubation.   
Real time quantitative PCR 
Total RNA was recovered from cells using Trizol reagent (Invitrogen, Carlsbad, CA) and 
DNase treated using the Turbo DNase® (Ambion; Houston, TX).  RNA concentration 







according to the manufacturer’s protocol.  Total RNA (2 µg) was reverse transcribed 
using the iScript cDNA synthesis kit (BioRad; Hercules, CA).  Primer sequences were: 
pig adiponectin, 5’-tgctgttgttgggagctgttc -3’ and 5’-aggaagcctgtgaagatggag -3’; porcine 
acetyl CoA carboxylase, 5’- atgtttcggcagtccctgat-3’ and 5’-tgtggaccagctgaccttga-3’, 
porcine acetyl CoA oxidase, 5’-ctcgcagacccagatgaaat -3’ and 5’-tccaagcctcgaagatgagt-3’, 
porcine AMPK, 5’-acatggctgagaagcagaag-3’ and 5’-ggtctcgatgaacaaccata-3’, porcine 
PPARα, 5’-cagcctccagcccctcgtc-3’ and 5’-gcggtctcggcatcttctagg-3’, porcine UCP3, 5’-
tggtgaaggtccgatttcag-3’ and 5’-aggcagagacaaagtggcag-3’, and porcine 18S, 5’-
ttaagccattaccagatata-3’ and 5’-agattcattcatgcattaag-3’, all sequences are sense and anti-
sense respectively.  Thermal cycler conditions for PCR reactions were 95 
o
C for 3 
minutes followed by 36 cycles of 95 
o
C for 30 seconds, 64 
o
C for 30 seconds, and 72 
o
C 
for 30 seconds.  Polymerase chain reaction products were cloned into pGEMT vector 
(Promega, Madison, WI) and sequenced for verification.  Real-time reactions were 
carried out on an iCycler real-time machine (BioRad, Hercules, CA) using the IQ™ 
SYBR Green Supermix kit (BioRad, Hercules, CA).  Plasmid containing the gene of 
interest was serially diluted to create a standard curve of gene copy number.  The mRNA 
abundance of each gene product was determined by regression analysis against the 
standard curve. The housekeeping gene, 18S RNA, did not differ among treatments or 
pigs. 
AMPK activity 
Cells and/or tissues were incubated with treatments for six hours in DMEM with 3% 
BSA.  Cell/tissue incubations were stopped by removal of the media and freezing in 







and/or tissue homogenates similar to Sakoda et al. (2002).  Briefly cells were lysed in  10 
vol/wt of Buffer A [50 mM Tris-HCl (pH 7.5), 50 mM NaF, 5 mM Sodium 
Pyrophosphate, 1 mM EDTA, 1 mM DTT, 0.1 mM Phenylmethylsulfonyl fluoride, 10 % 
glycerol] containing 1% Triton X-100, 5 µM aprotinin, leupeptin, and pepstatin.  
Following lysis samples were centrifuged at 12,000 x g for 20 minutes at 4
o
C to remove 
insoluble material.  Supernatants were collected and protein was quantitated using BCA 
reagents from Pierce (Rockford, IL).  Supernatants were aliquoted containing equal 
amounts of protein (700 µg) and immunoprecipitated overnight at 4
o
C with 2.5 µg anti-
AMPKα (Cell Signaling Technology/New England BioLabs; Beverly, MS).  The 
resultant immuno-complexes were precipitated using protein A agarose beads 
(Amersham Bioscience Corp; Piscataway, NJ) after which they were washed according to 
Sakoda et al. (2002).  The AMPK activity in the immunoprecipitates was determined as a 
function of phosphorylation of SAMS peptide as reported by Davies et al. (1989).  Assay 
reagents (Sakoda et al., 2002) were added directly to the immunoprecipitate and 
incubated for 15 minutes at 30
o
C while shaking.  Aliquots were removed and spotted 
onto circle filters (Whatman).  Filters were washed three times with 1% H3PO4, once with 
acetone and then air dried in a hood.  Filters were counted with 5 mL Cytoscint (ICN; 
Irvine, CA) and activity reported as fold increase over control.   
Immunoprecipitation and Western Blot Analyses 
Adipocytes were incubated with given treatments for six hours in DMEM with 3% BSA.  
Cell incubations were stopped by removal of the media and cells were washed twice with 
PBS.  Cells were lysed in  10 vol/wt of Buffer A [50 mM Tris-HCl (pH 7.5), 50 mM NaF, 







fluoride, 10 % glycerol] containing 1% Triton X-100, 5 µM aprotinin, leupeptin, and 
pepstatin.  Following lysis samples were centrifuged at 6,000 x g for 10 minutes at 4
o
C to 
remove insoluble material.  Supernatants were collected and protein was quantified using 
BCA reagents from Pierce (Rockford, IL).  Supernatants were aliquoted containing equal 
amounts of protein (250 µg) and immunoprecipitated at room temperature for 2 h using 
the Catch and Release v2.0 Reversible Immunoprecipitation System from Upstate Cell 
Signaling Solutions (Charlottesville, VA).  Phospho-AMPK Thr-172 (Cell Signaling 
Technologies, Danvers, MA) was immunoprecipitated with 1:100 primary antibody  
dilutions in 250 μl total volume.  Phospho-ACC Ser-79 (Upstate Biotechnology;)  was 
immunoprecipitated with 1:100 primary antibody dilutions in 250 μl total volume.  
Protein complexes were eluted from the column using 40 μl of 1X denaturing elution 
buffer containing βmercaptoethanol from the spin columns.  Total eluent protein was 
separated by SDS-PAGE using a 12% resolving gel and 4% stacking gel.  Proteins were 
transferred to a nitrocellulose membrane and probed with the primary antibody for 
phospho-AMPK or phospho-ACC at a concentration of 1:1000 at room temperature 
overnight in 5% BSA solution.  Blots were probed for 1 h at room temperature with a 
1:20,000 dilution of Goat-Anti-rabbit IgG –HRP antibody (Pierce Cat# 31460) and 
developed using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL).    
Statistical Analysis 
 All data were checked for normal distribution prior to mixed model analysis.  The 
fixed effects were treatment and time and the random effect was pig.  The main effects 







animals.  When protected by a significant F-test, mean separation was accomplished 
using the least squares means separation (pdiff) procedure (SAS, 1999; Cary, NC). 
 
3.4 Results 
Porcine Adiponectin mRNA expression is regulated by adiponectin, TNFα, and 
isoproterinol  
 To examine the regulation of porcine adiponectin mRNA abundance in porcine 
primary adipocytes, cells were isolated and cultured for 6 h in DMEM with 30 µg/mL 
adiponectin, 20 ng/mL leptin, 10 ng/mL TNFα, 10 ng/mL IL-6, 20 mU/mL insulin, 25 
mM glucose, 10 µg/mL LPS and 10
-6
 M isoproterenol.  Adiponectin mRNA abundance 
was up-regulated in porcine adipocytes by treatment with adiponectin itself by 5.7-fold (P 
< 0.05), by 6.6-fold with TNFα treatment (P < 0.01), and by 5.2-fold with isoproterenol 
treatment (P < 0.05) (Figure 3.1).  In addition, there was a trend for insulin up-regulation 
of adiponectin message in adipocytes (P < 0.1; Figure 3.1).  However, leptin, IL-6, 25 
mM glucose (high glucose), and LPS treatment did not affect adiponectin mRNA 
abundance after 6 h of culture (P >  0.05; Figure 3.1).   Data show differential regulation 
of adiponectin mRNA abundance by adipocytokines, inflammatory mediators, and 
regulators of lipid/energy balance in the adipocyte at acute 6 h time points.    
Adiponectin regulation of genes involved in cellular energy balance   
 Regulation of mRNA abundance of the genes, AMPK, ACC, PPARα, ACO and 
UCP3 in pig primary adipocyte cultures treated with 30 µg/mL recombinant porcine 
adiponectin  for 0, 30, 60, 120, 240, and 360 minutes were analyzed by real time 







the regulation of phospho-AMPK or phospho-ACC by adiponectin, and protein levels of 
PPARα were only evaluated at the 360 minute time point. 
Adiponectin regulation of AMPK mRNA,  phosphorylation of AMPK, and AMPK 
activity in porcine adipocytes 
 Porcine adiponectin transiently regulated mRNA abundance of AMPK over the 
360 minutes (Figure3.2).  Significant treatment effects were detected between control and 
adiponectin treated cells at 30, 120, 240, and 360 min (P < 0.05; Figure 3.2). The 
regulation of AMPK mRNA was differentially regulated depending on the time point of 
measurement.  Adiponectin treatment of adipocytes initiated a 4.4-fold increase in 
AMPK mRNA abundance at 30 minutes compared with control cells at the same time 
point (trt effect, P = 0.03; Figure 3.2).  At 60 minutes there is no difference between 
control and adiponectin treated cells on AMPK mRNA abundance, however by 120 
minutes adiponectin down-regulated AMPK by 2.0-fold (P = 0.03).  Followed by an 
increase in AMPK mRNA abundance with adiponectin treatment at 240 minute (P < 
0.05), and a trend for a decrease in AMPK mRNA at 360 minutes stimulated by 
adiponectin (P < 0.05).  Interestinly, the regulation of AMPK mRNA was differentially 
regulated by time in the control verses adiponectin treated cells.  While AMPK mRNA 
abundance declined in adiponectin treated cells from 30 minutes to the 6 h final time 
point (time effect, P < 0.05; Figure 3.2), there was a quadratic pattern of AMPK mRNA 
expression in the untreated cells (P < 0.05; Figure 3.2).   
 To determine if adiponectin regulation of AMPK mRNA abundance translates 
into regulation of AMPK protein expression we measure phosph-AMPK levels by semi-







6 h time course.   Due to large animal to animal variation in phosphorylation of AMPK 
we did not see any significant treatment effects of adiponectin or IL-6 compared to 
control cells (P > 0.05; Figure 3.3).  Interestingly, there was a trend for a significant 
effect of time seen in control, adiponectin and IL-6 treated cells (P < 0.1; Figure 3.3).  
The effect of time is similar between untreated and treated cells through the first 2 h of 
culture.  We saw a transcient acute increase in phospho-AMPK in the first 30 minutes of 
incubation followed by decreases through 120 minutes regardless of treatment.  
Adiponectin and IL-6 caused a sharp increase in phospho-AMPK  from 120 minutes to 
240 minutes (P < 0.1; Figure 3.3), and while the increase in phospho-AMPK was 
maintained through 360 min with adiponectin treated cells, IL-6 cells at 360 minutes had 
a decrease in phospho-AMPK from 240 min to 360 min (Figure 3.3).     As with phospho-
AMPK measurements we found large animal to animal variation in the measurements of 
AMPK activity and while there were trends for effect of time we did not detect 
significant difference of treatment or time in AMPK activity (P > 0.05; Figure 3.4). 
Adiponectin regulation of ACC mRNA and ACC-phosphorylation in porcine adipocytes 
 Acetyl-CoA Carboxylase mRNA abundance was measure over a 6 hour time 
course with or without adiponectin treatment (Figure 3.5).  There was a trend for a 
treatment effect of adiponectin on ACC mRNA abundance compared to control cells (P = 
0.1).  This trend can be attributed to an initial 18% increase of ACC mRNA at 30 minutes 
compared to control cells and small decreases in ACC mRNA at 120 and 240 minute 
cultures (Figure 3.5).  A time effect on ACC mRNA abundance was detected regardless 







 Acetyl CoA Carboxylase is regulated minute by minute by phosphorylation state.  
The inactive, phosphorylated, state of ACC is regulated by upstream kinases like AMPK.  
An experiment studying the effects of the adipocytokines, adiponectin and IL-6, on 
phospho-ACC protein expression detected large animal to animal variation, therefore, we 
were unable to detect any significant effects on phopho-ACC protein expression in these 
studies (Figure 3.6; P > 0.05).   
Adiponectin regulation of PPARα mRNA and PPARα  protein in porcine adipocytes 
 Peroxisome proliferator-activated receptor-alpha (PPARα) is a transcription factor 
which plays a major role in lipid metabolism.  The oxidative properties of cells have been 
linked to the activation of PPARα and it’s associated with a key gene involved in fatty 
acid oxidation, acetyl CoA oxidase (ACO).   We studied the regulation of PPARα mRNA 
by adiponectin over 6 h.  At 30 minutes adiponectin increased PPARα mRNA abundance 
by 32% compared with control cells (Figure 3.7; P < 0.01).  Transcript abundance then 
declined from 30 minutes to 120 minutes and remained unchanged for the next four hours 
of measurement (P < 0.05; Figure 3.7).  A similar trend of PPARα mRNA abundance was 
seen over the six hours for control cells too.   However, measurement of PPARα protein 
at 6h following adiponectin treatment was up-regulated compared with control cells in 
porcine adipocytes (Figure 3.8).     
Adiponectin regulation of ACO and UCP3 mRNA in porcine adipocytes 
 Regulation of ACO mRNA abundance by adiponectin in porcine adipocytes 
depicted similar results to other mRNA measure.  Intially after 30 minute incubations 







3.9).  However, remaining time points showed no difference in ACO mRNA compared to 
control cells.    
 Uncoupling protein 3 (UCP3) expression has been shown to be highly correlated 
with oxidative fatty acid metabolism in multiple cell types, therefore, determining the 
UCP3 message expression in adipocytes maybe indicative of the oxidative capacity of the 
adipocyte.  However, we did not detect difference in UCP3 mRNA abundance in 
adiponectin treated cells compared to the control (Figure 3.10).   Again, over the time 
course there was a significant decrease in UCP3 mRNA from 30 to 360 minutes 
regardless of treatment (P < 0.05; Figure 3.10).   
 
3.5 Discussion 
 The role of adiponectin in the regulation of energy metabolism could provide 
significant insight into the underlying mechanisms whole body energy balance in 
homeostatic states, as well as, provide valuable information regarding the dysfunction 
during metabolic diseases.  The hormonal and biochemical pathways associated with the 
development of obesity, insulin resistance, diabetes and metabolic syndrome are poorly 
understood.  Adiponectin is inversely correlated with obesity.  However, the regulation of 
adiponectin expression in adipose tissue and if adiponectin plays a role in 
autocrine/paracrine regulation of lipid metabolism in the adipocyte is not understood.   
Herein, we report the regulation of porcine adiponectin expression in vitro by TNFα and 
isoproterenol, and show that adiponectin augments its own expression.  We also define 
potentially key roles of adiponectin in the regulation of genes involved in fatty acid 







 Acute treatment of porcine adipocytes with adiponectin caused a significant 
increase in its mRNA abundance.  This is the first report of adiponectin regulating its 
own mRNA abundance.  This is particularly exciting, since Ajuwon and Spurlock (2005) 
reported adiponectin stimulates PPARγ2 protein expression in adipocytes, and that 
PPARγ induces adiponectin expression.  This mechanism may be an auto-regulatory loop 
by which adiponectin can regulate energy homeostasis in the adipocyte and thereby 
regulate chronic inflammation known to develop during period of abnormal energy 
balance.  
 We also determined the effect of other adipocytokines, insulin, high glucose 
concentrations (i.e., 5 vs. 25 mM), LPS and β-adrenergic agonist, isoproterenol, on 
adiponectin mRNA abundance.  In contrast to most reports in the literature, we found 
TNFα significantly increased adiponectin mRNA after 6 hours.  While the literature  
firmly supports the pro-inflammatory cytokine down-regulation of adiponectin mRNA 
and protein synthesis in 3T3-L1 adipocytes and human adipocytes (Fasshauer et al., 2002; 
Kappes and Loffler, 2000; Maeda et al., 2001), there could be discrepancies between 
culture conditions and time which cause these differences.  First, Fasshauer et al. (2002) 
cultured 3T3-L1 adipocytes for a chronic time period of 16 hours in the presence of 
TNFα, compared to our acute time point of 6h.  Second, there could be differences in 
glucose concentrations used in the culture media.  As Lin et al. (2005) demonstrated there 
are significant differences in the ability of 3T3-L1 adipocytes to respond to insulin 
stimulated glucose uptake depending if the cultures are maintained in euglycemic vs.  
hyperglycemic conditions.  Therefore, these cultures may have been carried out under 







from the regulation seen under hyperglycemic conditions, the condition in which our 
experiments were performed.  The same arguments could be used in discussing the 
difference seen in β-adrenergic agonist regulation of adiponectin in porcine primary 
adipocytes.  While Delporte et al. (2002) report a 30% down-regulation of adiponectin 
mRNA in human adipose explants by isoproterenol, we show approximately an  
induction of adiponectin mRNA in 6 hour cultures.  The differences between these 
experiments are not significant in acute and chronic regulation because the explants were 
cultured only for 8 hours.  However, part of the differential regulation may be attributed 
to the difference in adipose depot.  The human explants were extracted from visceral 
adipose tissue whereas we utilized the subcutaneous adipose depot.  In summary, there 
may be a common thread between TNFα and isoproterenol regulation of adiponectin at 
acute time point because both stimulate acute FFA release from the adipocyte.    
 The literature is very much divided on insulin regulation of adiponectin.  One of 
the most interesting findings we report here is adiponectin can significantly induce the 
transcription of its own transcript.  This is an intriguing concept that needs to be 
investigated further to determine if adiponectin plays a role in modulating its protein 
expression.   
 The autocrine regulation of adiponectin on lipid metabolism in the adipocyte has 
been reported by Jacobi et al. (2004) showing a down-regulation of lipogenesis by full 
length porcine adiponectin.  A potential mechanism for this was also demonstrated by 
Wu et al. (2003) who determined that globular adiponectin induces phosphorylation of 
AMPK  and ACC in rat primary adipocytes.  In pig adipocytes, adiponectin transiently 







regulation at the mRNA level over a 6 h period was cyclical for both enzymes, which 
perhaps reflects a tightly regulated coupling of these enzymes.  In the current work we 
also determine phosphorylation state of AMPK and ACC in pig adipocytes.  In contrast 
to Wu et al. (2003), although we saw numerical increases in phospho-AMPK and 
phospho-ACC they were not statistically significant.  These differences may be attributed 
to adipocytes derived from different species, different isoforms of adiponectin, or the fact 
that our culture system was under hyperglycemic conditions compared with their 
euglycemic conditions.  Altogether, these differences between culture systems could have 
a significant impact on the ability of adiponectin to regulate phosphorylation of AMPK 
and ACC.   
While there is little information on the oxidative capacity of the adipocyte, it has 
been well documented adiponectin induces oxidation in skeletal muscle and liver (Hu et 
al., 1996; Maeda et al., 1996; Nakano et al., 1996; Scherer et al., 1995).  Therefore, we 
hypothesized that adiponectin may impact the oxidative capacity of the adipocyte and 
convert the adipocyte from an energy storage cell to an energy consuming cell.  In fact at 
30 min time point, adiponectin stimulates PPARα and ACO mRNA indicating there is a 
potential for increased oxidative capacity of adipocytes. Adiponectin also increases 
PPARα protein in porcine adipocytes at 6 h of treatment, indicating there is an increased 
potential for oxidative capacity of the adipocyte given that PPARα is a key transcription 
factor in regulating genes of fatty acid oxidation. Additionally, adiponectin also 
significantly enhanced UCP3 mRNA at 6 h post treatment.   Altogether, these data 
suggest adiponectin can modulate glucose and lipid metabolism in the adipocyte 







oxidation.  This hypothesis is corroborated by Claret et al. (2005) who demonstrated 
tungstate fed to diet-induced obese rats increases fatty acid oxidation in adipose tissue 
and limits excessive production of ROS by induction of uncoupling proteins.  As well as, 
Li et al. (2005) demonstrated chronic stimulation of β-adrenegic signaling in adipocytes 
remodels WAT in two manners.  First, β-adrenergic stimulation induces an immediate 
pro-inflammatory response which is correlated with suppressed adipocyte-specific genes.  
Second, β-adrenergic activation stimulated mitochondrial biogenesis and up-regulated 
genes involved in fatty acid transport, activation and oxidation.  These data and the data 
presented here suggest the adipocyte has metabolic machinery and the plasticity to 
increase its catabolic activity to protect against excess nutrient induced insulin resistance 
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Figure 3.1 Regulation of adiponectin mRNA abundance in porcine adipocytes. 
Adipocytes from five pigs (n=5; 6 replicates within pig) were isolated and cultured for 6 
hours the presence of indicated treatments (30 µg/mL pAdn, 20 ng/mL leptin, 10 ng/mL 
TNFα, 10 ng/mL IL-6, 20 mU/mL insulin, 25 mM glucose, 10 µg/mL LPS and 10-6 M 
isoproterenol).  *indicates treatment different from control at P < 0.05; 
#
indicates 
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Figure 3.2Effect of adiponectin on AMPK mRNAabundance pig adipocytes from 0 to 6 
hours.   
Adipocytes were isolated and cultured in the presence or absence of adiponectin (30 
µg/mL adiponectin) (n=5 pigs; 6 replicates within pig).  Different letters indicate 
significant difference between control and adiponectin treated cells within a time point; P 
< 0.05; standard error = 0.26.  The main effect of time was significant at P = 0.04; 









Figure 3.3Effect of adiponectin and IL-6 on phosphorylation of AMPK in pig adipocytes.   
Adipocytes were cultured in the presence or absence of adiponectin (30 µg/mL) or IL-6 
(20 ng/mL).  (n=5 pigs; 6 replicates within pig) Standard error = 50, 144, 55, 35, 206, and 










Figure 3.4.Effect of adiponectin on AMPK activity in pig adipocytes 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 































Figure 3.5Effect of adiponectin on ACC mRNA abundance in pig adipocytes. 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 
(30 µg/mL adiponectin).  (n=5 pigs; 6 replicates within pig); different letters indicate 













Figure 3.6  Effect of adiponectin and IL-6 on phosphorylation of ACC in pig adipocytes. 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 
or IL-6 (30 µg/mL adiponectin and 20 ng/mL IL-6). (n=5 pigs; 6 replicates within pig) 













Figure 3.7.Effect of adiponectin on PPARα mRNA abundance in pig adipocytes. 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 
(30 µg/mL adiponectin).  (n=5 pigs; 6 replicates within pig) Different letters indicate 












Figure 3.8Effect of adiponectin on abundance of PPARα protein pig adipocytes. 
Adipocytes were cultured for 6 h in the presence (-) or absence (+) of adiponectin (30 
µg/mL adiponectin). (n=3 pigs; 6 replicates within pig) Different letters indicate 

















Figure 3.9. Effect of adiponectin on ACO mRNA abundance in pig adipocytes. 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 
(30 µg/mL adiponectin).  (n=5 pigs; 6 replicates within pig) Different letters indicate 













Figure 3.10 Effect of adiponectin on UCP3 mRNA abundance in pig adipocytes. 
Adipocytes were cultured for given time points in the presence or absence of adiponectin 
(30 µg/mL adiponectin).  (n=5 pigs; 6 replicates within pig).  Different letters indicate 








CHAPTER 4. PRO-INFLAMMATORY CYTOKINES AND GLUCOSE REGULATE 
EXPRESSION OF ADIPONECTIN RECEPTORS IN PORCINE ADIPOCYTES 
 
4.1 Abstract 
The anti-inflammatory activity of adiponectin may contribute to its insulin sensitizing 
effects.  Two adiponectin receptors have been identified as adipoR1 (R1) and adipoR2 
(R2), and down regulation of these receptors may promote insulin resistance.  The aim of 
this research was to determine if tumor necrosis factor α (TNFα), interleukin-6 (IL-6), or 
hyper-glycemic conditions regulate receptor expression in adipocytes, and whether 
inhibition of the JAK-STAT pathway by AG490 alters this regulation.  Primary 
adipocytes were prepared from subcutaneous adipose tissue of pigs (n=3).  Cells were 
incubated ± TNFα or IL-6 (30 ng/mL), with or without pretreatment of 10 μM AG490, in 
hyper-glycemic or normo-glycemic conditions for 6 h.  Total RNA was extracted and 
gene expression determined by real time PCR. There was no effect of cytokines at 5.5 
mM glucose for R1 expression.  However, there was a trend for a down-regulation of R2 
by AG490-TNFα (P < 0.07).  At 25 mM glucose, there was an increase in R1 by AG490-
TNFα treatment (P = 0.06).  R2 was marginally reduced by IL-6, but there was a 
reduction (P < .01) with AG490 plus IL-6.  High glucose caused a reduction of both 
receptors, whereas TNFα increased both in the high glucose media.   R1 (P < 0.1) and R2 








IL-6 and AG490 plus IL-6 (P < 0.05) reduced R1 and R2 expression, but only in the high 
glucose media.  Collectively, these data indicate that the effects of TNFα and IL-6 on 
adiponectin receptor expression are influenced by glucose concentration, and that the 
JAK-STAT pathway may be a determinant of adiponectin receptor expression. 
   
4.2 Introduction 
 Adipose tissue is a functional endocrine organ involved in regulating its own 
metabolism, as well as whole body energy homeostasis.  Adiponectin is an adipokine 
which moderates whole body glucose and energy metabolism.  Additionally, adiponectin 
is involved as a paracrine and autocrine regulator of white adipose tissue (WAT) 
metabolism (Wu et al., 2003; Aujwon et al, 2004, 2005; Jacobi et al., 2004; Kadowaki 
and Yamauchi, 2005).  The mechanisms of adiponectin action have been investigated by 
multiple researchers, who demonstrated different forms of adiponectin have potentially 
different biological functions (Pajvani et al., 2004).  The pathways which regulate the 
synthesis of different forms of adiponectin have been elusive; however, there are 
thoughts that different forms may be involved in regulating glucose metabolism versus 
regulating inflammation.   
While the form of adiponectin may have a critical role in determining 
physiological responses, receptor mediated cell-signaling will be integral in 
understanding adiponectin’s physiological responses.  Adiponectin signaling appears to 
be predominantly through the recently cloned adipoR1 and adipoR2 receptors (Yamauchi 
et al., 2003).  AdipoR1 is ubiquitously expressed and most abundantly expressed in 








Hyperinsulinemia induces a two-fold increase of adipoR1 in skeletal muscle (Debard et 
al., 2004).  Additionally, Chinetti et al. (2004) demonstrated pharmacological regulation 
of adipoR2 by synthetic PPAR ligands, thiazolidinediones (TZD) and fibrates in human 
macrophages.  Bluher et al. (2005) demonstrated both receptors are expressed in adipose 
tissue, and adipoR2 seems to be more abundant in porcine subcutaneous adipose tissue 
than adipoR1 (Ding et al., 2004).  Therefore, it seems plausible that the regulation of 
adiponectin receptors in white adipose tissue could be important in regulation of glucose 
metabolism and whole energy balance.  In fact, Tuschida et al. (2005) provided the first 
evidence demonstrating activation of PPARs may play a critical role in adiponectin and 
adiponectin receptor expression.   This information led them to hypothesize that 
activation of PPARα suppresses inflammation in white adipocytes in part by suppressing 
adipocyte hypertrophy.  Secondly, dual activation of PPARα and PPARγ may lead to 
induction of adiponectin receptors, as well as regulation of different forms of adiponectin 
present.   Previously we reported adiponectin suppress lipogenesis in porcine adipocytes 
(Jacobi et al., 2004) and induces PPARα, both findings supporting Tuschida et al. (2005) 
report that adiponectin induces PPARs and reduces inflammation.  In addition, reports 
from our lab have also shown adiponectin activates PPARγ2 and inhibits TNFα and IL-6 
secretion (Ajuwon et al., 2005).  Therefore, the hypothesis of the current study was that 
down-regulation of adiponectin receptors by pro-inflammatory cytokines antagonizes the 
anti-inflammatory action of adiponectin to potentiate the innate immune response in 











Animals and adipocyte isolation 
Adipose tissue was obtained from five male castrates weighing approximately 90-110 kg 
consuming a nutritionally-complete diet ad libitum.  The pigs were maintained according 
to protocols approved by the Purdue University Animal Care and Use Committee, and 
killed in the Purdue University abattoir according to USDA regulations.  Subcutaneous 
adipose tissue was removed from the dorsal depot located over the cervical spine, and 
transported in buffered saline (37
o
C, 0.15 M NaCl, 10 mM HEPES, pH 7.4) to the 
laboratory.  Adherent skeletal muscle was removed, and the tissue was cubed and sliced 
with a Stadie-Riggs microtombe.  Approximately 6-7 g of sliced tissue was minced, 
rinsed with saline, and transferred to a flask containing 15 mg collagenase (100 U/mL 
final concentration; Worthington BioChemical, Lakewood, NJ USA).  Following a 30-35 
minute digestion period, isolated adipocytes were washed through a 290 μm screen with 
warmed Krebs Ringer bicarbonate buffer (pH 7.4) containing 10 mM HEPES, 5 mM 
glucose, and 3% bovine serum albumin (Fraction V, essentially fatty acid free, Invitrogen 
Life Technologies, Carlsbad, CA USA) to remove all other cell debris.    
 The isolated adipocytes were resuspended in culture media (DMEM Sigma 
D6780; St. Louis, MO USA) containing 3% BSA and 10 mM HEPES at a final 
concentration of approximately 2 x 10
5 
cells per mL and aliquoted immediately into 15 
mL polypropylene scintillation vials for incubation.  Porcine adipocytes were then treated 
with either recombinant porcine TNFα (30 ng/mL), recombinant porcine IL-6 (30 
ng/mL), 10 µM AG490, 10 µM darglitazone, and/or differing levels of glucose 








Real time quantitative PCR 
Total RNA was recovered from cells using Trizol reagent (Invitrogen, Carlsbad, CA) and 
DNase treated using the Turbo DNase® (Ambion; Houston, TX).  RNA concentration of 
sample was determined using the RiboGreen® assay (Molecular Probes, Eugene, OR 
USA) according to the manufacturer’s protocol.  Total RNA (2 µg) was reverse 
transcribed using the iScript cDNA synthesis kit (BioRad; Hercules, CA).  Primer 
sequences were: pig adipoR1, 5’-attgctacaggactcattcg-3’ and 5’-tagccattacggattact-3’; pig 
adipoR2, 5’-attacggttaacgttact -3’, 5’-aggcttatcgactatggtta -3’and pig 18S, 5’-
ttaagccattaccagatata-3’ and 5’-agattcattcatgcattaag-3’, all sequences are sense and anti-
sense, respectively.  Thermal cycler conditions for PCR reactions were 95 
o
C for 3 
minutes followed by 36 cycles of 95 
o
C for 30 seconds, 62 
o
C for 30 seconds, and 72 
o
C 
for 30 seconds.  Polymerase chain reaction products were cloned into pGEMT vector 
(Promega, Madison, WI) and sequenced for verification of identity.  Real-time reactions 
were carried out on an iCycler real-time machine (BioRad, Hercules, CA) using the IQ™ 
SYBR Green Supermix kit (BioRad, Hercules, CA).  Plasmid containing the gene of 
interest was serially diluted to create a standard curve of gene copy number.  The mRNA 
abundance of each gene product was determined by regression analysis against the 
standard curve. The housekeeping gene, 18S RNA, did not differ among treatments or 
pigs.   
Immunoprecipitation of Phospho-Proteins and Western Blots 
Adipocytes were incubated with given treatments for two to six hours in DMEM 
containing 3% BSA.  Cell incubations were stopped by removal of the media and cells 








Tris-HCl (pH 7.5), 50 mM NaF, 5 mM Sodium Pyrophosphate, 1 mM EDTA, 1 mM 
DTT, 0.1 mM Phenylmethylsulfonyl fluoride, 10 % glycerol] containing 1% Triton X-
100, 5 µM aprotinin, leupeptin, and pepstatin.  Cell lysates were then centrifuged at 6,000 
x g for 10 minutes at 4
o
C to remove any insoluble material.  Supernatants were collected 
and protein was quantified using BCA reagents from Pierce (Rockford, IL).  Supernatants 
protein (250 µg) was then immunoprecipitated at room temperature for 2 h using the 
Catch and Release v2.0 Reversible Immunoprecipitation System from Upstate Cell 
Signaling Solutions (Charlottesville, VA). The immunoprecipitate reaction was in a total 
volume of 250 μl and in the presence of AdipoR1 (G-001-44; Phoenix Pharmaceuticals; 
Belmont,CA)  or AdipoR2 (G-001-23;Pheonix Pharmaceuticals; Belmont, CA)  
antibodies at 1:100 or 1:50 dilutions, respectively.  Protein complexes were eluted from 
the column using 40 μl of 1X denaturing elution buffer containing βmercaptoethanol 
from the spin columns.  The protein was then separated by SDS-PAGE using a 12% 
resolving gel and 4% stacking gel.  Proteins were transferred to a nitrocellulose 
membrane and probed with the primary antibody for AdipoR1 or AdipoR2 at a 
concentration of 1:1000 at room temperature overnight in 5% BSA solution.  Blots were 
probed for 1 h at room temperature with a 1:20,000 dilution of Goat-Anti-rabbit IgG –
HRP antibody (Pierce Cat# 31460) and developed using the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Cat #34080).    
Statistical Analysis 
 All data were checked for normal distribution prior to mixed model analysis.  The 
fixed effects were treatment and time, and the random effect was replicate.  The main 








significant F-test, mean separation was accomplished using the least squares means 
separation (pdiff) procedure (SAS, 1999; Cary, NC). 
 
4.4 Results 
Adiponectin receptors are differentially regulated over time and inflammatory cytokines, 
TNFα and IL-6 modulate  
 To access adipoR1 and adipoR2 mRNA abundance in primary porcine 
adipocytes, cells were cultured for 0, 2, 4 and 6 hours in the euglycemic conditions and 
then collected to total RNA isolation.  Porcine primary adipocytes express adipoR1 and 
adipoR2 mRNA.  Interestingly, the mRNA abundance was differentially regulated over 
time.  AdipoR1 mRNA abundance was significantly up-regulated over time in culture 
from 0 to 6 hours (Figure 4.1; P < 0.05), while adipoR2 mRNA abundance was 
significantly decreased from 0 to 6 hours of culture (P < 0.05; Figures 4.2).  
Glycemic conditions may modulate adiponectin receptor expression by pro-inflammatory 
cytokines 
 It has been well documented hyperglycemia is highly correlated with the 
development of insulin resistance and adiponectin has insulin-sensitizing properties.  
However, the understanding of how adiponectin exerts these effects is in the early stages 
of development, and insulin resistance is correlated with pro-inflammatory mediators. To 
address the relationship between adiponectin and pro-inflammatory mediators we 
investigated how the cytokines, TNFα and IL-6 modulate adiponectin receptor mRNA  
abundance under normal glycemic and hyperglycemic conditions.  Porcine adipocytes 








6 (30 ng/mL) with or without 10 μM AG490 (JAK-STAT inhibitor) in both 5.5 mM and 
25 mM glucose.  Under normal glycemic (5.5 mM glucose) conditions, TNFα and IL-6 
had no effect on adipoR1 mRNA abundance (Figure 4.3).  However in the presence of 25 
mM glucose, adipoR1 mRNA abundance was up-regulated compared to control when 
treated with AG490 + TNFα (Figure 4.3; P = 0.06).   There was a trend for down-
regulation of adipoR2 mRNA abundance when adipocytes were treated with the 
combination of AG490 + TNFα in 5.5 mM glucose (Figure 4.4; P =0.8).  In 25 mM 
glucose media, AdipoR2 mRNA abundance was marginally reduced by IL-6, but 
significantly reduced when treated with AG490 + IL-6 (Figure 4.4; P < 0.05).  To 
determine if there was a correlation between adipoR1 and adipoR2 message and protein 
expression preliminary semi-quantitative western blots were ran and analyzed for 
receptor protein abundance basal media condition, 30 ng/mL TNFα, and 30 ng/mL IL-6 
at three different levels of glucose supplementation (5.5, 25, and 40 mM).  Preliminary 
results showed no differences in adipoR1 and adipoR2 protein expression in the presence 
or absence of TNFα or IL-6 at normo- or hyper-glycemic conditions (Figures 4.5 and 4.6; 
P > 0.05).  Collectively, these data indicate that the effects of TNFα and IL6 on 
adiponectin receptor expression are influenced by glucose concentration, and that the 
JAK-STAT pathway may be a determinant of adiponectin receptor mRNA expression, 
however, acutely protein levels were not regulated by these factors. 
AdipoR1 and R2 were not acutely regulated at the protein level by glycemic condition or 
PPARγ agonist 
 While we found marginal regulation of adipoR1and adipoR2 mRNA abundance 








abundance of the adiponection receptors by these pro-inflammatory cytokines in a small 
sample size, we want to investigate if PPAR signaling hormones or pathways regulate 
receptor expression.  To address this question porcine adipocytes were cultured for 6 
hours in basal media alone, plus 30 ug/mL porcine adiponectin, plus 10 μM darglitazone, 
or the combination of adiponectin and darglitazone in normal or high glucose media.  
AdipoR1 protein expression was not affected by treatment with adiponectin, darglitazone, 
or glucose levels (Figure 4.7).  Similar to adipoR1 protein expression, there was no 
significant change in adipoR2 proteins expression by any of the treatments at 5.5 mM 
glucose concentrations (Figure 4.8).  However, adiponectin, darglitazone and adiponectin 
plus darglitazone increased adipoR2 protein expression in porcine adipocytes cultured in 
25 mM glucose containing media (Figure 4.8; P < 0.05).   These data suggest   
differential regulation of adipoR2 by adiponectin and darglitazone under differing 











Regulation of whole body energy homeostasis is regulated by complex 
biochemical reactions that are modulated by substrate and product abundance, as well as, 
hormonal regulation.  The complexity in maintenance of energy homeostasis is correlated 
with the abundance of adipose tissue.  Adipose tissue once thought to be a passive energy 
storage depot is now known to produce adipokines needed to maintain whole body 
energy homeostasis. An imbalance of adipose tissue mass (too little or too much) is 
associated with diseases metabolic imbalance.  The aim our study was to investigate 
changes in adiponectin receptors expression in cell culture that mimic physiological  
associated with metabolic disease.    
Herein, we provide evidence that pro-inflammatory cytokines, glycemic 
conditions, adiponectin and PPARγ agonist play a role in the differential regulation of 
adipoR1 and adipoR2. These findings are of considerable significance for several reasons.  
Firstly, in addition to obesity and insulin resistance, chronic inflammation accompanies 
the pre-diabetic condition known as the metabolic syndrome (Yudkin, 2003).  Secondly, 
obesity is accompanied with an increase in macrophage infiltration into white adipose 
tissue (Weisberg et al., 2003; Xu et al., 2003a) and both adipocyte and macrophage gene 
profiles reflect inflammation.  Furthermore, our lab has shown adiponectin to suppress 
TNFα and IL-6  production in macrophages and adipocytes (Ajuwon and Spurlock, 2005; 
Wulster-Radcliffe et al., 2004).  Now we found TNFα plus a JAK/STAT inhibitors tends 
to down-regulate adipoR2 mRNA abundance in adipocytes culture in euglycemic 
conditions, and under hyperglycemic conditons IL-6 with inhibition of JAK/STAT 








hyperglycemic culture adipocytes.  In addition, adipoR2 protein abundance was increased 
in porcine adipocytes culture in hyperglycemic conditions with the addition of PPARγ 
agonist, darglitazone and porcine adiponectin compared to control cells.  This regulation 
could indicate differing physiological functions for adipoR1 and adipoR2.   
  Under conditions of hyperinsulinemia, adipoR1 is induced two-fold in skeletal 
muscle (Debard et al., 2004).  Hyperinsulinemic conditions are reflective of an insulin 
resistant state, suggesting there is regulation of adiponectin receptors in glucose sensitive 
tissues during altered metabolic conditions.  Consistent with these findings, we 
demonstrated under acute inflammatory conditions that TNFα down-regulates adipoR2 
expression in primary adipocytes.  This down-regulation could lead to inability of 
adiponectin to exert anti-inflammatory effects on the adipocyte and lead to the increased 
infiltration of macrophages associated with chronic inflammation and obesity.  This 
hypothesis is reasonable considering we have shown that adiponectin up-regulates its 
mRNA in WAT (data unpublished) and adiponectin and darglitazone increase adipoR2 
protein expression in adipocytes under hyperglycemic conditions.  Moreover, this 
regulation of adipoR2 is supported by Chinetti et al. (2004), who demonstrated 
pharmacological regulation of adipoR2 by synthetic PPAR ligands, thiazolidinediones 
(TZD) and fibrates in human macrophages.  Bluher et al. (2005) demonstrated both 
receptors to be expressed in adipose tissue, and adipoR2 seems to be more abundant in 
porcine subcutaneous adipose tissue verses adipoR1 (Ding et al., 2004).  Furthermore, 
Tuschida et al. (2005) have provided the first evidence demonstrating activation of 
PPARs may play a critical role in adiponectin and adiponectin receptor expression in 








and inflammation by demonstrating the PPARα agonist, WY-14643 directly increased 
expression of both adiponectin receptors in WAT and also decreased monocyte 
chemoattractant protein-1 in adipocytes and macrophages.   
Taken together, these data along with evidence we provide here linking pro-
inflammatory cytokines, hyperglycemic state, adiponectin and PPARγ agonist to the 
regulation of adipoR2 in adipocytes, makes a very strong argument for the hypothesis 
that the activation of PPARα suppresses inflammation in white adipocytes in part by 
suppressing adipocyte hypertrophy.  Secondly, dual activation of PPARα and PPARγ 
may lead to induction of adiponectin receptors, as well as, regulation of different forms of 
adiponectin present compared to total adiponectin.  Additionally, this is also supported by 
the fact we show adiponectin can stimulate PPARα mRNA and protein in isolated 
porcine adipocytes.   
Collectively, these data indicate that the effects of TNFα and IL6 on adiponectin 
receptor expression are influenced by glucose concentration, and that the JAK-STAT 
pathway may be a determinant of adiponectin receptor mRNA expression, and acutely 
protein levels of adipoR2 may be regulated by adiponectin and PPARγ agonist.  
Interestingly, the adipocyte plays a crucial role in regulating its own metabolism and by 
maintaining the cell size in a “normal” metabolic state. This in turn will allow for the 
production of adipokines which maintain normal glucose homeostatsis that is lost during 











Ajuwon, K. M., and M. E. Spurlock. 2005. Adiponectin inhibits lps-induced nf-kappab 
activation and il-6 production and increases ppargamma2 expression in 
adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R1220-1225. 
Ajuwon KM, Jacobi SK, Kuske JL, Spurlock ME.  2004.  Interleukin-6 and interleukin-
15 are selectively regulated by lipopolysaccharide and interferon-gamma in 
primary pig adipocytes.  Am J Physiol Regul Integr Comp Physiol. 2004 
Mar;286(3):R547-53 
Bluher, M. et al. 2005. Regulation of adiponectin receptor r1 and r2 gene expression in 
adipocytes of c57bl/6 mice. Biochem. Biophys. Res. Commun. 329: 1127-1132. 
Chinetti, G., C. Zawadski, J. C. Fruchart, and B. Staels. 2004. Expression of adiponectin 
receptors in human macrophages and regulation by agonists of the nuclear 
receptors pparalpha, ppargamma, and lxr. Biochem. Biophys. Res. Commun. 314: 
151-158. 
Debard, C. et al. 2004. Expression of key genes of fatty acid oxidation, including 
adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 
47: 917-925. 
Ding, S. T., B. H. Liu, and Y. H. Ko. 2004. Cloning and expression of porcine 
adiponectin and adiponectin receptor 1 and 2 genes in pigs. J. Anim. Sci. 82: 
3162-3174. 
Jacobi, S. K. et al. 2004. Cloning and expression of porcine adiponectin, and its 
relationship to adiposity, lipogenesis and the acute phase response. J. Endocrinol. 
182: 133-144. 
Kadowaki, T., and T. Yamauchi. 2005. Adiponectin and adiponectin receptors. Endocr. 
Rev. 26: 439-451. 
Pajvani, U. B. et al. 2004. Complex distribution, not absolute amount of adiponectin, 
correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J 









Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T.  2005.  
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases 
adiponectin receptors and reduces obesity-related inflammation in adipose tissue: 
comparison of activation of PPARalpha, PPARgamma, and their 
combination.Diabetes. 2005 Dec;54(12):3358-70. 
Weisberg, S. P. et al. 2003. Obesity is associated with macrophage accumulation in 
adipose tissue. J. Clin. Invest. 112: 1796-1808. 
Wu, X. et al. 2003. Involvement of amp-activated protein kinase in glucose uptake 
stimulated by the globular domain of adiponectin in primary rat adipocytes. 
Diabetes 52: 1355-1363. 
Wulster-Radcliffe, M. C., K. M. Ajuwon, J. Wang, J. A. Christian, and M. E. Spurlock. 
2004. Adiponectin differentially regulates cytokines in porcine macrophages. 
Biochem. Biophys. Res. Commun. 316: 924-929. 
Xu, H. et al. 2003. Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830. 
Yamauchi, T. et al. 2003a. Cloning of adiponectin receptors that mediate antidiabetic 
metabolic effects. Nature 423: 762-769. 
Yudkin, J. S. 2003. Adipose tissue, insulin action and vascular disease: Inflammatory 













Figure 4.1 Regulation of AdipoR1 mRNA overtime in pig adipocytes. 
Adipocytes were cultured for given time points in media with 5.5 mM glucose.  (n=5 
pigs; 6 replicates within pig)   Time effect P < 0.05.  Means without common letter differ 
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Figure 4.2Regulation of AdipoR2 mRNA overtime in pig adipocytes. 
Adipocytes were cultured for given time points in media with 5.5 mM glucose.  (n=5 
pigs; 6 replicates within pig)   Time effect P < 0.05.  Means without common letter differ 
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Figure 4.3Effect of TNFα and IL-6 on AdipoR1 mRNA abundance in pig adipocytes 
under euglycemic and hyperglycemic conditions. 
Adipocytes were cultured for 6 h in the presence or absence of TNFα (30 ng/mL), AG490 
(10uM), and/or IL-6 (30 ng/mL).  (n=3 pigs; 6 replicates within pig).  Different letters 
















Figure 4.4 Effect of TNFα and IL-6 on AdipoR2 mRNA abundance in pig adipocytes 
under euglycemic and hyperglycemic conditions. 
Adipocytes were cultured for 6 h in the presence or absence of TNFα (30 ng/mL), AG490 
(10uM), and/or IL-6 (30 ng/mL).  (n=3 pigs; 6 replicates within pig).  Different letters 

















Figure 4.5 Regulation of AdipoR1 protein by pro-inflammatory cytokines under 
euglycemic and hyperglycemic conditions. 
Adipocytes were cultured for 6 h in the presence or absence of TNFα (30 ng/mL) or IL-6 
(30 ng/mL) under varying concentrations of glucose. (n=2 pigs; 6 replicates within pig) 
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Figure 4.6 Regulation of AdipoR2 protein by pro-inflammatory cytokines under 
euglycemic and hyperglycemic conditions 
Adipocytes were cultured for 6 h in the presence or absence of TNFα (30 ng/mL) or IL-6 
(30 ng/mL) under varying concentrations of glucose. (n=2 pigs; 6 replicates within pig) 
standard error = 30.6 
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Figure 4.7 Regulation of AdipoR1 protein by adiponectin and darglitazone under 
euglycemic and hyperglycemic conditions. 
Adipocytes were cultured for 6 h in the presence or absence of adiponectin (30 μg/mL) or 
darglitazone (10 μM) under varying levels of glucose.  (n=2 pigs; 6 replicates within pig) 












Figure 4.8 Regulation of AdipoR2 protein by adiponectin and darglitazone under 
euglycemic and hyperglycemic conditions. 
Adipocytes were cultured for 6 h in the presence or absence of adiponectin (30 μg/mL) or 
darglitazone (10 μM) under varying levels of glucose.  (n=2 pigs; 6 replicates within pig)  













Induction of insulin resistance is a major complication associated with many metabolic 
abnormalities linked to obesity.  It has recently been established that hyperglycemic 
conditions can induce insulin resistance in adipocytes and perpetuate the inflammatory 
response associated with development of metabolic syndrome.  However, it has not been 
investigated as to whether adiponectin, the insulin sensitizing and anti-inflammatory 
adipokine, functions to combat glucose intolerance by inhibiting or reversing the effects 
seen by hyperglycemic treatments.  Here, we analyzed the effects of hyperglycemia on 
insulin sensitivity in pig adipocytes, as well as, determining the effect of adiponectin on 
hyperglycemic treated 3T3-L1 adipocytes.  In pig adipocytes, we found 25 and 40 mM 
glucose in the culture media is enough to induce hyperglycemic inhibition of insulin-
stimulated glucose uptake (P < 0.05).  Glucose induced insulin resistance in primary pig 
adipocytes could not be attributed to changes in phosphosphorlation of the insulin 
receptor or its down-stream target Akt (P > 0.05).  To test a more chronic (2 days) 








mouse derived adipocyte culture system.  Similar to the effects seen in acute porcine 
adipocyte cultures hyperglycemia inhibited insulin stimulated 2-deoxyglucose uptake in 
3T3-L1 adipocytes too (P < 0.05), and 24 hour treatment with adiponectin could not 
reverse the insulin resistance.  Again, difference in phosphorylation of the insulin 
receptor and Akt could not be detected in hyperglycemic culture cells compared with 
control cells.  Interestingly, although adiponectin did not appear to impact insulin 
signaling pathways in these cells to combat hyperglycemic conditions it did have an 
effect on inflammatory pathways in the adipocyte.  Adiponectin reduced the production 
of intracellular ROS under hyperglycemic conditions in 3T3-L1 adipocytes (P < 0.05).  
Taken together these data implicate adiponectin suppressing intracellular inflammation 
during hyperglycemia, but was not able to reverse hyperglycemia induced insulin 
resistance effect on glucose uptake.   
 
5.2 Introduction 
 The development of insulin resistance is a pleiotropic condition which is impacted 
by many genetic and environmental factors.  Insulin resistance is a condition which 
develops over time and is highly associated with obesity and type II diabetes.  The degree 
of insulin resistance is directly linked to glucose tolerance.  Once a certain level of insulin 
resistance is met, there is a severe deterioration of glucose homeostasis in multiple tissues 
throughout the body.    
Adipocytes have come to the forefront of being major regulators of whole body 
energy metabolism, and in beginning to understand the role of the adipocyte it has 








abnormal metabolic states associated with disease and morbidity.  The mechanisms 
behind these phenotypes are beginning to be unraveled.  In fact, hyperglycemic and 
hyperinsulinemic states result in impaired insulin receptor signaling (Tang et al., 2001).  
Others have demonstrated 3T3-L1 cells under hyperglycemic conditions have  impaired 
IRS-1 phosphorylation and down-stream insulin signaling (Lin et al., 2005).  
Hyperglycemia has also been shown to induce reactive oxygen species (ROS) in rat 
primary adipocytes and 3T3-L1 adipocytes (Lu et al., 2001; Lin et al. 2005).  Increased 
ROS is associated with increased inflammation, and an increased inflammatory state is 
highly associated with obesity.   
The adipocytokine adiponectin has been shown to have anti-inflammatory and 
insulin-sensitizing properties (ref).  Our lab has previously demonstrated that adiponectin 
can inhibit lipopolysacharide induced cytokine production in treated adipocytes and 
macrophages (Ajuwon et al., 2004; Ajuwon and Spurlock, 2005; Wulster-Radcliffe et al., 
2004).  Given this information it seemed logical adiponectin, an insulin-sensitizing 
adipocytokine, mechanistically may regulate insulin stimulated glucose uptake in 
adipocytes and the production of ROS, thereby alleviating the effects of hyperglycemia 
induced insulin-resistance.    
Therefore, the first aim of this research was to determine if hyperglycemia could 
impair glucose uptake in porcine adipocytes, and if so, does it occur through impairment 
of insulin signaling pathways.  Secondly, to investigate using the 3T3-L1 adipocytes 
model of hyperglycemia induced insulin resistance if adiponectin could reverse the 
inflammatory state induced by high glucose restore insulin sensitivity.      









Animals and adipocyte isolation 
Adipose tissue was obtained from male castrates weighing approximately 90-110 kg, and 
consuming a nutritionally-complete diet ad libitum.  The pigs were maintained according 
to protocols approved by the Purdue University Animal Care and Use Committee, and 
killed in the Purdue University abattoir according to USDA regulations.  Subcutaneous 
adipose tissue was removed from the dorsal depot located over the cervical spine, and 
transported in buffered saline (37
o
C, 0.15 M NaCl, 10 mM HEPES, pH 7.4) to the 
laboratory.  Adherent skeletal muscle was removed, and the tissue was cubed and sliced 
with a Stadie-Riggs microtombe.  Approximately 6-7 g of sliced tissue was minced, 
rinsed with saline, and transferred to a flask containing 15 mg collagenase (100 U/mL 
final concentration; Worthington BioChemical, Lakewood, NJ USA).  Following a 30-35 
minute digestion period, isolated adipocytes were washed through a 290 μm screen with 
warmed Krebs Ringer bicarbonate buffer (pH 7.4) containing 10 mM HEPES, 5 mM 
glucose, and 3% bovine serum albumin (Fraction V, essentially fatty acid free, Invitrogen 
life technologies, Carlsbad, CA USA) to remove all other cell debris.   The cells were 
resuspended in culture media (DMEM Sigma D6780; St. Louis, MO USA) with 3% BSA 
and 10 mM HEPES at a final concentration of approximately 2 x 10
5 
cells per mL and 
aliquoted immediately into 15 mL polypropylene scintillation vials for incubation.   
Cell Culture 
3T3-L1 murine fibroblast (ATCC; Manassas, VA) were seeded in 12-well plates or 3.5 








CO2 in low glucose DMEM containing 10% calf serum (GIBCO, Carlsbad, CA).  Two-
days post-confluence (Day 0), cells were induced to differentiate with low glucose 
medium containing 10% fetal bovine serum (GIBCO), 150 nM insulin, 250 μM 
dexamethasone, and 0.5 mM isobutylmethylxanthine (IBMX) for two days (Day 2).  
Thereafter, cells were maintained in fresh medium containing only insulin for another 8 
to 10 days.  Cells were used between days 10 and 14 post-differentiation.  Glucose 
treatments (5.5 or 25 mM) were applied to cells 48 hours prior to harvest and 30 μg/mL 




Pig adipocytes were assayed for [1-
3
H]2-Deoxyglucose (Amersham) uptake under the 
following conditions.  Pig adipocytes were cultured in 5.5, 25, or 40 mM glucose for 
three hours and then media was spiked with 0.33 μCi of  [1-3H]2-deoxyglucose/mL for 5 
minutes followed by media being spiked with increasing concentrations of insulin (0, 1, 
5, 20, and 100 nM) for 15 minutes.  Transport assay was terminated by removal of media 
and two washes with cold PBS.  A hundred microliter alliqout of cells was added to 
scintillation cocktail and counted for glucose uptake.  All samples were standardized to 
cells which were spiked with labeled glucose and washed immediately for a background 
count.  3T3-L1 glucose uptake was performed similarly to Lin et al. (2005) except cells 
were not glucose starved for 30 minutes prior to the assay.   
Immunoprecipitation of Phospho-Proteins and Western Blots 
Adipocytes were incubated with treatments for six hours in DMEM with 3% BSA.  Cell 








Cells were lysed in  10 vol/wt of Buffer A [50 mM Tris-HCl (pH 7.5), 50 mM NaF, 5 
mM Sodium Pyrophosphate, 1 mM EDTA, 1 mM DTT, 0.1 mM Phenylmethylsulfonyl 
fluoride, 10 % glycerol] containing 1% Triton X-100, 5 µM aprotinin, leupeptin, and 
pepstatin.  Following lyses samples were centrifuged at 6,000 x g for 10 minutes at 4
o
C to 
remove insoluble material.  Supernatants were collected and protein was quantified using 
BCA reagents from Pierce (Rockford, IL).  Supernatants were aliquoted containing equal 
amounts of protein (100 µg) and immunoprecipitated at room temperature for 2 h using 
the Catch and Release v2.0 Reversible Immunoprecipitation System from Upstate Cell 
Signaling Solutions (Charlottesville, VA).   Phospho-Akt (Thr 308) antibody (Cat # 9275; 
Upstate Cell Signaling) was immunoprecipitated with 1:100 primary antibody dilutions in 
250 μl total volume.  Akt antibody (Cat # 9272; Upstate Cell Signaling) was 
immunoprecipitated with 1:500 primary antibody dilutions in 250 μl total volume. 
Phospho-insulin receptor (Tyr) (BioSource) was immunoprecipitated with 100 ug total 
protein and a 1:50 primary antibody dilution in 250 ul total volume.  Protein complexes 
were eluted from the column using 40 μl of 1X denaturing elution buffer containing β-
mercaptoethanol.  Total eluent protein was separated by SDS-PAGE using a 12% 
resolving gel and 4% stacking gel.  Proteins were transferred to a nitrocellulose 
membrane and probed with the primary antibody. All antibodies were used in a 1:500 
dilution to probe blots at room temperature overnight in 5% BSA solution or 5% milk 
powder in TTBS.  Blots were probed for 1 h at room temperature with a 1:20,000 dilution 
of Goat-Anti-rabbit IgG –HRP antibody (Pierce Cat# 31460) and developed using the 









Measurement of Intracellular ROS Generation 
Cells were washed in Krebs-Ringer biocarbonate buffer and then incubated in the dark 
with fluorescent probe 5-(and-6)-carboxy-2´,7´-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA) *mixed isomers (10 uM; Invitrogen CAT# C400) for 45 minutes at 
37
o
C.  The flourensence of CM-DCF was analyzed using a fluorescent plate reader at an 
excitation wavelength of 435 nm and emission at 550 nm.  ROS production was 
determined by an H2O2 standard curve (10-200 nmol/ml).  
Statistical Analysis 
 All data were checked for normality before being analyzed using the mixed model 
analysis.  The fixed effect was the treatment and the random effect was the replicate.  
When protected by a significant F test, mean separation was accomplished using the least 
squares means separation (pdiff) procedure (SAS, 1999; Cary, NC). 
 
5.4 Results 
Hyperglycemia inhibits insulin-stimulated glucose uptake in porcine adipocytes and 3T3-
L1 adipocytes 
 Insulin resistance is highly correlated with hyperglycemia, but the mechanisms 
for this induction of insulin resistance are not well understood.  However, recently 
obesity and the development of insulin resistance have been linked to chronic 
inflammation, and adiponectin has been implicated as an insulin-sensitizing hormone. 
First, we wanted to determine if hyperglycemia could induce insulin resistance in pig 
adipocytes, and if so does it occur through direct inhibition of insulin signaling.  As 








inhibit insulin stimulated 2-deoxyglucose uptake in pig adipocytes (P < 0.01).  However, 
pre-treatment with adiponectin for 2 hours could not reverse this inhibition on glucose 
uptake (data not shown) during this acute time frame.  To examine a more chronic model 
of insulin resistance used 3T3-L1 adipocyte cultures.  At 10 day post-differentiated 
adipocytes were changed to either 5.5 or 25 mM glucose media for 24 hours.  The 
following day either vehicle or adiponectin was added to the cell media for 24h.  Twenty-
four hours after adiponectin treatment all cells were given 2-deoxyglucose followed by 
corresponding insulin treatment.  Similar to results in acute porcine adipocyte cultures, 
even with more chronic adiponectin treatment the hormone could not reverse 
hyperglycemic inhibition of insulin stimulated glucose uptake (Figure 5.2; P < 0.01).  
Effect of hyperglycemia on insulin signaling pathway in pig adipocytes and 3T3-L1 
adipocytes  
 To further extend these results we wanted to see if the mechanism for 
hyperglycemic induced insulin resistance is related to insulin signaling pathway.  
Therefore, we measured phospho-Akt at Thr 308, total Akt, and phospho-insulin receptor 
at Tyr 92.  Conversely, to what we expected there was no significant change across 
treatments for phospho-Akt, Akt and phosphor-IR in pig adipocytes which had glycemic 
inhibition of insulin stimulated glucose uptake (Figure 5.3, 5.4, and 5.5).  Interestingly, 
we also measured these same proteins in the 3T3-L1 experiments and again found no 
difference between treatments on phosphorylation state of Akt or the insulin receptor (P > 









The role of hyperglycemic conditions and adiponectin on development of intracellular 
ROS in 3T3-L1 adipocytes 
 To  investigate whether adiponectin could reverse the increase in intracellular  
ROS species associated with hyperglycemic conditions in 3T3-L1 cells we used a 5-(and-
6)-carboxy-2´,7´-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA)*mixed 
isomers assay to measure intracellular ROS.  In contrast to the insulin signaling data, we 
measured significantly elevated intracellular ROS under hyperglycemic conditions which 
were abrogated with adiponectin treatment (Figure 5.9; P < 0.05).   
   
5.5 Discussion 
 These experiments provide a limited view of hyperglycemic induced mechanisms 
involved in insulin resistance.  Our data show hyperglycemic cell culture conditions 
induce insulin resistance in primary porcine adipocytes, as it relates to insulin stimulated 
glucose uptake. This is a significant contribution to the literature which consistently 
reports pig adipocytes are only mildly sensitive to insulin stimulation (Mills et al., 1999).  
However, conventional primary adipocyte methodologies supplement culture media with 
25 mM glucose (Walton et al., 1996; Mills et al., 1999), possibly inducing an insulin 
resistant phenotype.  Although adiponectin is known to be an insulin sensitizing hormone, 
we were not able to reverse the effect of hyperglycemic conditions by pre-treatment with 
adiponectin.  There are a few plausible reasons why adiponectin was not able to reverse 
insulin-resistance.  First, in pig primary adipocyte cultures the length of time primary 
cells can be cultured is extremely acute (6-8 hours).  This very small duration of 








glucose.  Furthermore, the form of adiponectin involved in glucose and insulin tolerance 
signaling pathways could be the high molecular weight or the cleaved protein and not the 
full length protein. In fact, Tuschida et al. (2005) reported the high molecular weight 
isoforms of adiponectin may be the form of the protein involved in modulating insulin 
resistance (Tuschida et al., 2005).  If this is the case, then there is the possibility the 
recombinant expressed full length adiponectin, which we used in our cultures, is not 
mediating insulin sensitivity pathways but functions to regulate inflammatory mediators 
in the adipocyte which indirectly affect insulin sensitivity. 
 Similar to the pig adipocyte experiments, we also determined recombinant 
expressed full length adiponectin did not reverse hyperglycemic induced inhibition of 
glucose uptake in 3T3-L1 adipocytes.  Given that this system allowed for more chronic 
exposure for adiponectin treatment the same arguments from above still apply to the 
reasons we may not have seen a reversal of insulin resistance in these cells.  In contrast to 
Lin et al (2005) we could not show hyperglycemic conditions inhibited phosphorylation 
of key components of the insulin signaling pathway.  These results may be attributable to 
inclusion of 10% serum in culture media if 3T3-L1 cells throughout the assay system.  
Serum components may have interfered with ability to pick up reduction in 
phosphorylation of the insulin receptor and its down-stream effector Akt.   
 As depicted by the increase of intracellular ROS, inflammation does appear to be 
induced in 3T3-L1 adipocytes by hyperglycemic conditions.  Interestingly, under low 
glucose conditions ROS are also present within the cells.  This may be due to an acute 
increase of intracellular fatty acids within the cell stimulating an acute inflammatory 








in adipocytes we do know that it can stimulate PPARα in these cells thereby eliciting an 
increase in oxidative capacity of the adipocyte.  This initial increase in intracellular fatty 
acid could lead to an acute inflammatory response from these cells.  It will be interesting 
to determine if this is a prolonged effect of adiponectin treatment at more chronic time 
points.  An alternative point could be IL-6 is actually acting in an anti-inflammatory 
capacity in these short time frames.  This would not be completely unwarranted because 
Bruunsgard et al. (2005) have shown IL-6 release from muscle tissue during exercise has 
anti-inflammatory properties.   
 Researchers have found hyperglycemia has a significant effect on the 
development of intracellular ROS in other cell types (ref), and Lin et al. (2005) reported 
hyperglycemia induces intracellular ROS in 3T3-L1 adipocytes.  If adiponectin is insulin-
sensitizing it seems plausible adiponectin could reverse the induction of ROS in 3T3-L1 
cells.  Our data demonstrated adiponectin does reduce intracellular ROS compared to 
high glucose treated cells alone. Recombinant adiponectin does protect the adipocyte 
against increases in ROS in adipocytes, but did not impact insulin sensitivity pathways. 
These findings lend support to the hypothesis that different forms of adiponectin are 
impacting glucose metabolism pathways and inflammatory pathways in the adipocyte in 
different ways.  This theory adds more complexity to understanding how adiponectin 
works as an insulin sensitizing compound and an anti-inflammatory compound in the 
adipocyte to protect against metabolic abnormalities associated with obesity and type II 
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Figure 5.1 Hyperglycemic inhibition of insulin stimulated glucose uptake in pig 
adipocytes 
Adipocytes were and cultured with increasing concentrations of glucose for three hours 
followed by 2h insulin treatment with 2-deoxyglucose in the media. n = 3 pigs; error bars 
are stardard error = 12.77; *mean significantly different from 5.5 mM glucose treatment; 







































2-Deoxyglucose uptake in Pig Adipocytes 
5.5 mM Glucose 25 mM Glucose
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Figure 5.2 Hyperglycemic inhibition of insulin stimulated glucose uptake in 3T3-L1 
adipocytes 
 is not attenuated by 24h treatment with adiponectin.  Adipocytes were cultured for 24 h 
in euglycemic or hyperglycemic media followed by 24 h treatment with 30 ug/ml 
adiponectin.  At 48 h post glucose treatments cells were treated with insulin in the 
presence of 2-deoxyglucose for 2 h.  n=6 wells/treatment; *Indicate significant difference 






































2-Deoxyglucose uptake in 3T3-L1 Adipocytes 
5.5 mM Glucose 5.5 mM Glucose + pAdn
25 mM Glucose 25 mM Glucose + pAdn












Figure 5.3 Hyperglycemic regulation of Phospho-Akt in pig adipocytes. 
Adipocytes were cultured for 6 h in different glucose containing media with increasing 































Glucose & Insulin  Regulation of Phospho-Akt  
in Pig Adipocytes   










Figure 5.4 Hyperglycemic regulation of Total Akt protein in pig adipocytes. 
Adipocytes were cultured in euglycemic and hyperglycemic media for 6 h and stimulated 




























Glucose & Insulin Regulation of Total Akt Protein  
in Pig Adipocytes 










Figure 5.5 Hyperglycemic regulation of phosphorylation of the insulin receptor in pig 
adipocytes. 
Adipocytes were cultured in euglycemic and hyperglycemic media for 6 h and stimulated 



































Glucose & Insulin Regulation of Phospho-IR 
in Pig Adipocytes 










Figure 5.6 Hyperglycemic regulation of phosphorylation of Akt in 3T3-L1 adipocytes 
Adipocytes were cultured in euglycemic and hyperglycemic media for 48 h and 































Hyperglycemic & Adiponectin Regulation of Phospho-Akt 
in 3T3-L1 Adipocytes 
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Figure 5.7 Hyperglycemic regulation of total Akt protein in 3T3-L1 adipocytes 
.Adipocytes were cultured in euglycemic and hyperglycemic media for 48 h and 



























Hyperglycemic & Adiponectin Regulation of Total Akt 
in 3T3-L1 Adipocytes 
5.5 mM Glucose 5.5 mM Glucose + pAdn










Figure 5.8.Hyperglycemic regulation of phosphorylation of the insulin receptor in 3T3-
L1 adipocytes 
Adipocytes were cultured in euglycemic and hyperglycemic media for 48 h and 
































Hyperglycemic & Adiponectin Regulation of Phospho-IR 
in 3T3-L1 Adipocytes 
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Figure 5.9Adiponectin regulation of intracellular ROS activity in 3T3-L1 adipocytes 
cultured under euglycemic and hyperglycemic conditions. 
n=3 per treatment. Main effect of treatment was significant at P =  0.034; different letters 
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CHAPTER 6. SUMMARY 
The adipocyte has come to the forefront of having pleitropic functions in energy 
metabolism and a role in immune function.  Although the role of energy metabolism is 
thought to be fairly well characterized, it appears the intricate balance between energy 
homeostasis in the adipocyte and abnormal metabolic state is tightly linked.   We provide 
evidence that the regulation of energy balance in the adipocyte is a critical component of 
maintaining a normal glycemic and insulinemic state in the pig and 3T3-L1 adipocytes, 
and that the adipocytokine, adiponectin, plays a critical role in this balance.  First, we 
provided evidence of adiponectin impacting lipid metabolism in the adipocyte by directly 
decreasing lipogenesis.  Additionally, we provide evidence of the mechanism behind this 
reduction in lipogeneic capacity may be partially mediated by induction of AMPK 
activation which impacts the phosphorylation of ACC, thereby, inhibiting a key 
regulatory enzyme in lipid synthesis.  This theory has also been demonstrated by Wu et 
al., (2003) in rat adipocytes using the globular form of adiponectin.  The inhibition of 
ACC leads to a reduction in the conversion of acetyl CoA to malonyl CoA.  Malonyl 
CoA functions acutely as an allosteric regulator of the rate limiting enzyme, CPTI, which 
tightly controls oxidative capacity of the cell.  By decreasing the flux of malonyl CoA to 
the cell one has increased the capacity for activity of CPTI and thereby, increasing the 








which shows adiponectin acutely stimulates AMPK, PPARα, ACO, and UCP3 mRNA in 
pig primary adipocytes, as well as, up-regulates PPARα protein in these cells.  The last 
three genes of interest are all known to play important roles in increased oxidative 
capacity of cells.   
 The regulation of lipid metabolism and storage of excess energy in the adipocyte 
are traditionally linked to adipose tissue.  More recently it appears this physiology is the 
component of adipocytes which couple it to the inflammatory tone of the adipose tissue, 
as well as the body. Research has shown 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR), a synthetic compound, which activates the energy sensing 
kinase, AMPK, can dose-dependently increase adiponectin gene expression in human 
adipose tissue (Lihn et al., 2004).  In addition, AICAR attenuates the release of TNFα and 
IL-6 from human adipose tissue. Thus, reduced concentrations of these cytokines, 
increased levels of adiponectin, and AMPK activity appear to play a role in the insulin-
sensitizing effects of AICAR and adiponectin. This is consistent with the findings that 
adiponectin attenuates the translocation of nuclear factor kappa B (NFκB) to the nucleus 
of adipocytes stimulated with lipopolysacharide (LPS) (Ajuwon and Spurlock 2005).  
Attenuation of NFκB translocation is coupled with an expected decrease in production of 
pro-inflammatory cytokines.  These date support a tight link between adipocyte energy 
metabolism and immune function of the adipocyte.   
 Additionally, we demonstrate adiponectin induces its own expression in pig 
adipocytes.  Data suggesting adiponectin has tight control over energy metabolism of the 
cell and regulation of adipocytokines involved in whole body energy homeostasis and 








research from our lab confirms adiponectin can increase PPARγ2 expression in the 
adipocyte.  Therefore, these data suggest a strong theory that adiponectin may be a master 
regulator of energy metabolism, glucose homeostasis and inflammation in the adipocyte.  
In addition, we have shown adiponectin regulates PPARα mRNA and protein abundance 
in the adipocyte and Tsuchida et al. (2005) report PPARα increases adiponectin receptor 
expression.  These researchers also demonstrated that dual activation of PPARα and 
PPARγ had additive effects in reversing insulin resistance in KKAy obese mice, which 
provides supporting evidence adiponectin regulates the tight control energy metabolism 
in the adipocyte.   
Furthermore, we also provide evidence that pro-inflammatory cytokines, glucose 
concentrations, adiponectin and PPARγ agonist are involved in differential regulation of 
adipoR1 and adipoR2. These data suggest potential mechanisms for regulation of 
adiponectin and adiponectin signaling and the inverse correlation of the adipokine the 
development of obesity and insulin resistance.  The chronic inflammation known to 
accompany metabolic syndrome (Yudkin, 2003) antagonizes the ability of adiponectin to 
regulate the adipocyte microenvironment which plays a critical role in modulating whole 
body insulin resistance.   
 The regulation of adiponectin and the adiponectin receptors have key roles in the 
regulation of insulin resistance. Although our data did not find that recombinant 
adiponectin could reverse hyperglycemic inhibition of insulin stimulated glucose uptake 
in adipocytes, we did find evidence adipocytes cultured in high glucose media that are 
insulin resistant have increased intracellular ROS and treatment with adiponectin 








adiponectin, its receptors, glucose homeostasis and inflammation unfolds. The research 
reported here provides key pieces to the mechanisms of adiponectin physiology 
suggesting adiponectin functions in an autocrine and paracrine mechanism to regulate its 
synthesis and its receptor synthesis.  The complexity of the involvement of adipocyte 
physiology in regulation of whole body energy homeostasis is a marvel to how well 
regulated the human body is at modifying signaling pathways under complex metabolic 
stress; and to how excess or depletion of adipose tissue can negatively impact the ability 
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